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INTERRATER VARIABILITY BETWEEN LOCAL AND CENTRAL 
PATHOLOGISTS IN AN INDUSTRY SPONSORED ADJUDICATION 
PROGRAM 
ALISON MICHELE OCCHIUTI 
ABSTRACT 
Background: Adjudication is a standardized, objective, and often blinded mechanism 
designed to assess clinical events with increased accuracy. It is performed by a 
centralized committee of independent reviewers, who are specialized, expert physicians 
who have no involvement with either the treatment of study subjects or the trial sponsor. 
Adjudication can decrease variability and bias in study results and increase the likelihood 
of correct identification, assessment, and categorization of clinical events such as 
potential malignancies diagnosed through histopathology. Histopathology is highly 
variable due to the subjective nature of the assessments. 
Thesis: If it is the case that there are clinically significant discrepancies between local and 
central diagnoses and that central adjudication yields more accurate diagnoses than a 
local pathologist, then it should be accepted that adjudication ought to be more widely 
used in clinical trials to assess histopathology-related safety outcomes and endpoints. 
Methods and Statistics: This is a retrospective cross-sectional study assessing interrater 
variability between local and central diagnoses of biopsy samples in a clinical trial setting 
using kappa scores and percent agreement. Certified Professional Coders (CPC) and 
central pathologists used the International Classification of Diseases for Oncology 
revision 3 (ICD-O 3) to codify the local and central assessments to permit comparison. 
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Three statistical groups (group A: the full dataset, group B: pathology sub-specialty 
reading groups, and group C: non-melanoma skin cancers versus all other malignancies) 
were assessed for interrater variability in seven separate analyses: neoplasm versus non-
neoplasm (analysis 1), benign versus malignant including non-neoplasms (analysis 2.1), 
benign versus malignant excluding non-neoplasms (analysis 2.2), discrepancies in 
morphology and/or behavior including non-neoplasms (analysis 3.1), discrepancies in 
morphology and/or behavior excluding non-neoplasms (analysis 3.2), all discrepancies 
leading to differences in treatment (analysis 4.1), and all discrepancies leading to 
difference in treatment with round 1 matches removed (analysis 4.2).  
Results: 602 cases comprised the dataset. Based on kappa scores, there is near perfect 
agreement between the central and local lab diagnoses in analyses 1, 2.1, and 2.2 in group 
A (all cases in the dataset). The percent agreement for these analyses is above 90%. The 
group A (full dataset) kappa score and percent agreement decreased to 0.59 and 68.3%, 
respectively, in analysis 3.1 (discrepancies in morphology and/or behavior codes, 
including non-neoplasms). When non-neoplasms were removed (analysis 3.2), the kappa 
score and percent agreement were 0.52 and 57.0%, respectively. In group C, NMSC had 
substantial kappa agreement in analyses 1, 2.1, and 2.2, whereas all other malignancies 
had near perfect kappa agreement. All percent agreements were above 88% and 
surpassed the minimally acceptable threshold for interrater percent agreement in 
healthcare (80%). Group B divided the data set into 10 sub-specialty reading groups. 
Kappa scores ranged from 0.66 (GYN) to 1.00 (lung) in analysis 1; the analysis 1 kappa 
score for lymphoma was 0.55, but this was not statistically significant. In analysis 2.1, 
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lung and sarcoma had the highest kappa scores (1.00) and dermatology and GYN had the 
lowest (0.71). As in analysis 1, the kappa score for lymphoma was 0.55 but was not 
statistically significant. When non-neoplasms were removed from analysis 2.2, 6 of the 
10 sub-groups had kappa scores of 1.00, but all 6 had sample sizes less than 10. Percent 
agreement ranged from 80 to 100 percent. When all cases were considered regardless of 
number of rounds of review (analysis 4.1), about 90% of diagnoses would have similar 
courses of treatment. All sub-groups except sarcoma reached the minimally acceptable 
agreement rate in healthcare (80%). In the remaining 33% of cases that did not have 
matching diagnoses in round 1 (analysis 4.2), 34% may have different courses of 
treatment depending on whether the local or central diagnoses was used. Mid-study 
updates to the charter and CPC/reviewer manuals and processing of specimens did not 
have a significant impact on results.  
Conclusion: Although there is little discrepancy between local and central pathologists on 
whether malignancies exist among samples, there is discord regarding specific diagnoses 
and their associated treatments. Adjudication can assist in decreasing this discordance in 
order to develop the most specific and accurate safety profile for a compound.   
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INTRODUCTION 
  
The goal of pharmaceutical development is to bring effective drugs and 
treatments to the market through the most cost-effective process. The most efficient 
clinical trials yield unambiguous data on efficacy and safety. Overwhelming success on 
both counts permits rapid advancement to the next phase of trials and decreases the 
probability of repeat studies, while unequivocal failure allows pharmaceutical companies 
to more quickly reallocate resources to a new and potentially more fruitful project. The 
rate at which unequivocal data is provided through clinical trials can be increased through 
independent central review, also known as adjudication, because this practice increases 
accuracy and decreases bias and variability. The utility of adjudication is well established 
for assessing efficacy endpoints as well as cardiovascular safety endpoints, such as Major 
Adverse Cardiac Events (MACE) as defined by the Hicks criteria.1
Examples include cardiovascular death, non-fatal myocardial infarction (MI), and non-
fatal stroke. Its use in assessing safety endpoints in other therapeutic areas is largely 
unexplored. It is likely that practicing central adjudication for oncologic safety endpoints 
can produce similar benefits, facilitating more consistent diagnoses. Adjudication is 
tightly controlled through training, testing, and data presentation which leads to an 
increase in reliability and consistency. Central review of tissue samples related to 
potential malignancy events can corroborate or refute a local diagnosis from a site. This 
would yield a higher rate of unequivocal results, increasing efficiency for studies 
regarding oncologic safety in drug development. 
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Any practice that can improve efficiency in clinical studies is significant, as it 
could offer tremendous economy for a pharmaceutical industry that faces a failure rate of 
more than 90%. Based on estimates between 2006 and 2015, the likelihood that a drug in 
a phase I study will eventually be approved is 9.6% (failure rate of 90.4%). The 
likelihood that a drug will advance from Phase II to Phase III is only 30.7% (failure rate 
of 69.3%).2  In May 2016, the Tufts Center for the Study of Drug Development estimated 
the cost of bringing a new drug to market (from Phase I through to approval) is estimated 
at $1.3 billion. Considering research and development (R&D) expenses and the current 
failure rates mentioned above, the estimate rises to about $4 billion.3,4
If central adjudication can introduce significant efficiency in clinical trials with 
oncologic safety endpoints, this would in turn entail massive savings during 
pharmaceutical development.  
Central Adjudication 
 Adjudication is a standardized, objective, and often blinded mechanism designed 
to assess clinical events with increased accuracy. It is performed by a centralized 
committee of independent reviewers (IRs), who are specialized, expert physicians who 
have no involvement with either the treatment of study subjects or the trial sponsor.5 
These committees are referred to as an adjudication committee or clinical events 
committee (CEC). Utilizing complex clinical definitions can lead to heterogenous and 
often subjective outcomes, and central adjudication is an effective way of curbing this 
tendency through standardization and objectivity.6(p695) 
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Central adjudication is already widely used, but is by no means ubiquitous. In a 
meta-analysis of 314 articles from five influential general medical journals covering 
randomized clinical trials, use of adjudication was mentioned in 105 articles (33.4%).6 
Krumholz-Bahner et al. assessed 35 newly identified molecular entities approved in the 
United States and 88 drug approvals in the European Union between January 2013 and 
April 2014. Central adjudication of the primary endpoints was used in 69% of approvals 
in the United States, and in 41% for the European Union, with most endpoints being 
efficacy related. Twenty-nine studies used central adjudication to assess efficacy, but 
only eight studies adjudicated exclusively safety endpoints.  Fifteen studies used 
adjudication to investigate a combination of both.7  
 In the absence of a “truth standard” - a standard believed to give the true state of a 
patient or true value of a measurement - adjudication can help facilitate increased 
accuracy in results.8 The United States Food and Drug Administration (FDA) encourages 
the use of truth standards in clinical trials to “demonstrate that the results obtained are 
valid and reliable.”8(p22) Areas of medicine that have an undefined or nebulous truth 
standard could benefit from the practice of adjudication as an alternative. Although 
adjudication does not replace a truth standard, it can streamline data by removing variable 
interpretations and utilization of definitions which can cloud the dataset.9 A more 
homogenous dataset is easier to analyze and makes it more likely that a clear and concise 
conclusion can be reached.   
 Limited CEC membership combined with uniform training, data presentation, and 
application of definitions keep variability low and precision and accuracy high.9(p265),10 
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The entire adjudication process, from identification of a case through independent 
review, is documented in a charter. The charter includes the following: the process for 
collecting and processing source materials from the sites, definitions and explanations of 
terms relevant to making an assessment, minimum requirements for making 
assessments/how to handle cases that do not meet the minimum requirements, electronic 
case report form (eCRF) description, committee membership, training, testing 
requirements, read paradigm, and a bias minimization plan.11,12  
 Adjudication committees are often confused with data safety monitoring boards 
(DSMBs), but each has a separate role in a clinical trial.  The purpose of a DSMB is to 
ensure ongoing safety of trial participants and continuous validity and scientific integrity 
of the trial.10(p112),11(p54) The DSMB generates periodic risk/benefit assessments and safety 
reports; the adjudication committee generates independent harmonized assessments of 
study outcomes. The DSMB is usually unblinded to treatment assignment of participants; 
the adjudication committee is almost always blinded to this information.10(p112) 
Bias 
 “Bias is systematic error that leads to distortion of true treatment effects.”13 This 
is different from random error or imprecision, which leads to a study outcome that is 
different from the “truth” due to statistical uncertainties related to obtaining a random 
sample. Random error is inevitable, but can be addressed retrospectively during statistical 
analysis. Risk of bias is also inherent in randomized clinical trials and can be mitigated 
prospectively through a study design that includes adjudication.  
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 Bias in clinical trials includes selection bias, detection bias, performance bias, and 
attrition bias.14 Selection bias occurs when individuals are recruited, screened, and/or 
enrolled into a trial in such a way that systematic differences between study arms are 
created. Selection bias can also result from enrolling subjects that are not generalizable to 
the intended study population. Detection bias is a systematic difference in outcome 
determination and results. Performance bias refers to systematic differences in the type of 
care and attention provided to study participants, which may give both caregivers and 
subjects inclinations as to which treatment arm they are assigned. Attrition bias is a 
systematic difference in study withdrawals from each group. Study withdrawal leads to 
incomplete or missing information which can alter interpretation of results.14  
Adjudication can address performance bias and detection bias through 
maintaining independence from sites and sponsors. Maintaining independence permits 
the adjudication committee to be more objective in making assessments. Selection bias 
and attrition bias are controlled for through study design - whether they can be mitigated 
through adjudication is not addressed in this paper. 
The dual role of study investigator and clinical physician leads to potential for 
detection and performance bias. The goals of clinical practice and clinical investigation 
are different, which complicates objectivity.10(p115) Physicians acting as both caregiver 
and investigator could have personal and emotional histories with certain patients, which 
can create difficulty in remaining objective. Adjudication committees are completely 
separated from patient care, which eliminates this problem. 
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 Adjudication decreases performance bias and resulting detection bias through 
creating distance between clinical subjects and those responsible for making assessments. 
Personal preferences can skew investigator assessments of certain outcomes.5(p56),13(p596) 
As stated by KR Cox, “the desire for a successful outcome is felt so strongly in both 
patients and investigator that objectivity cannot be guaranteed. Both have an emotional 
stake, overt or occult, in the result. Further, the giving of any treatment…is a strong 
psychotherapeutic stimulus in itself.”15  
If an unblinded investigator favors one treatment over another, performance bias 
may lead to detection bias. The investigator may follow those on the preferred treatment 
more closely, consequently identifying outcomes more often than those in the non-
preferred group.13(p596) Even blinded investigators with knowledge of all treatment 
options may believe that a subject is on a particular treatment arm. Subjects perceived to 
be on the preferred treatment arm could be monitored differently. Even when recording 
lists of numbers or simple data, mistakes in transcription are often in the direction most 
personally favored by the investigators.16 Because adjudication obscures all identifying 
information between a subject and investigator, it all but eliminates the potential for an 
emotional connection and personal preference that could lead to performance and 
detection biases. 
Results based on bias undermine the integrity of a study, but adjudication can 
mitigate the potentially negative effects of performance and detection bias. Adjudication 
increases the veracity of study results through maintaining independence from study sites, 
investigators, and subjects. It is important to remove or minimize bias in studies to any 
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extent possible to maximize the safety and efficacy of treatments predicated upon those 
studies, and adjudication is a valuable tool in accomplishing this. 
Variability 
 The clinical trial model decreases variability and biasing through randomization 
and blinding, among other methods, such as following a protocol.  Variability measures 
the spread in a dataset – spread is simply a reference of the level of difference between 
certain data points or characteristics. Adjudication can further decrease variability 
through standardized training and monitoring as well as judicious committee 
membership. The larger and more complicated the clinical trial, the greater the potential 
for variability. For example, the principal investigator is responsible for creating and 
managing a study team most capable of accurately implementing study procedures, but 
variability regarding team size, years of experience, specialization, and division of labor 
is inevitable.11(p57)  
 Studies with complex outcome definitions or study procedures are at an elevated 
risk for variability. Examples include medical events based mostly on subjective 
interpretation due to lack of standardized definitions and/or subject reported information, 
such as cardiovascular composite outcomes.17 Events where there is systematic 
misclassification based on accepted clinical definitions also lead to high variability.5(p57) 
Criteria for medical events may differ between clinical practice and study protocol, and in 
these instances study personnel could easily confuse definitions while alternating 
between clinical and investigative duties. Study teams working outside of their areas of 
expertise could mistakenly identify, fail to identify, or miscategorize events as well. For 
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example, a rheumatologist acting as principal investigator for a rheumatoid arthritis trial 
might incorrectly categorize, or even miss, a cardiac event.  
An adjudication committee eliminates these issues. Members are selected based 
on the type of clinical events requiring review and are standardized in review criteria 
through training and consistent monitoring. Adjudication committee members may be 
practicing physicians, but they do not have to alternate between seeing study versus non-
study patients because they do not see patients enrolled in the study for which they 
adjudicate.  
  Variability in study execution can lead to distorted study outcomes, which could 
under or overestimate true treatment effect. In a simulated tumor growth and tumor 
growth measurement model, researchers found that variability in assessing tumor size led 
to attenuation of treatment effect (hazard ratio closer to one) and increased type II error.18 
Several studies have shown that adjudication can change event classification in 20-30% 
of cases, thereby creating a more well-supported dataset.6(p699) 
 One such study was the second Platelet IIb/IIIa Antagonist for the Reduction of 
Acute Coronary Syndrome Events in a Global Organization Network Trial (PARAGON-
B). Analyses showed that site and central diagnoses of MI disagreed 23% of the time. For 
95% of discrepant cases, letters were sent to sites that providing rationale for the central 
decision. Site investigators then returned the letters either confirming or refuting the 
central diagnosis; in 80% of cases (307 cases) site investigators came to agree with the 
central assessments. The remaining 20% (75 cases) were reviewed by a faculty 
committee of cardiologists. The faculty committee agreed with the site investigator in 
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only 10 of the 75 cases. The recorded outcome for these 10 cases were determined by the 
site investigator; in all other cases (372 of 382) the recorded outcome was the outcome 
determined by the adjudication committee.19   
In the TRIM trial, the adjudication committee changed the final assessment in 
24.3% of site reported events; the total number of endpoints decreased by 11.9%.17(p774) 
The TRITON, RECORD, and PLATO studies of acute coronary syndromes also showed 
a decrease in total site reported cardiovascular endpoints after adjudication by a central 
committee. Adjudicated data in the IMPACT II, GUSTO IIb, and PURSUIT acute 
coronary syndrome trials showed opposite results. In the IMPACT II and GUSTO IIb 
trials, statistically significant differences between the treatment arms were observed when 
investigator data was used but not when adjudicated data was used.5(p58)  
Data safety monitoring boards depend on accurate assessments of endpoints to 
determine when/if studies should be halted. Regulatory agencies also rely on accurate 
assessments when determining when/if a drug application should be approved. 
Adjudication can provide extra assurance that the data used to make such important 
decisions is reliable. That said, authorities should independently audit studies where the 
difference between central and local assessments could have a major impact on study 
outcomes.17(p776),20 
Safety Monitoring 
 Adjudication increases the likelihood of correct identification, assessment, and 
categorization of clinical events essential for accurate data interpretation. The FDA 
requires sponsors to monitor pre- and post-marketing clinical trials for events indicating 
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possible safety concerns.21 Sponsors collect information on adverse events (any untoward 
medical occurrence associated with the use of a drug in humans, regardless of whether it 
is considered drug-related) to reveal potential adverse reactions (any adverse event for 
which there is a reasonable possibility that the drug caused the adverse event).22 Adverse 
events and reactions meeting certain criteria are required to be reported to the FDA and 
may also be required on product labeling. For example, “potential serious risks” and 
“serious and unexpected suspected adverse reaction[s]” for drugs being tested under an 
investigational new drug application (IND) must be reported to the FDA within fifteen 
calendar days of becoming aware of the event.22  
The Food and Drug Administration Amendments Act of 2007 (FDAAA) 
authorized the FDA to require (when deemed necessary) post-marketing studies to assess 
known serious risks, safety signals of serious risks, and identify any unexpected serious 
risks. The Food and Drug Modernization Act of 1997 (FDAMA) also requires that annual 
status reports to be submitted to the FDA for drugs approved under a New Drug 
Application (NDA) or Accelerated New Drug Application (ANDA) for the first time.23,24 
The annual reports must include a summary of new or updated information that might 
affect safety, efficacy, or labeling of the investigational product. This safety information 
from various sources including new toxicology data from nonclinical laboratory studies, 
published clinical trial data, “reports of clinical experience pertinent to safety,” and status 
reports of post-marketing study commitments.23 Sponsors must continue to submit annual 
reports until they are notified in writing that post-marketing requirements have been 
fulfilled or that the sponsor is released from further commitments.   
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 The FDA recommends a systematic approach to clinical trial safety monitoring 
that depends on accurate recognition and designation of clinical events. Adjudication 
increases the likelihood of both. Safety determinations can involve multiple endpoints 
even when some preexisting safety concerns are known. Sponsors must periodically 
review data in aggregate, collecting data from completed and ongoing studies, to reveal 
potential causal relationships between events and the intervention under investigation. 
Examples of areas of concern include: events occurring more frequently in the 
intervention group versus a control group, and/or a clinically relevant increase in the 
prevalence of a serious adverse reaction over what is expected based on previous 
data.22,25  
 Adjudication can supplement safety monitoring plans for studies conducted under 
NDAs or ANDAs as well as for post-marketing studies. Adjudication data can be 
presented to DSMBs in addition to or in place of site-generated data. When provided 
together, DSMBs can compare the two datasets to illuminate study data inconsistencies. 
Consistent differences in categorization of events between the adjudication committee 
and a particular site or differences in classification of one type of event between the 
adjudication committee and all sites could be causes for concern.      
Oncologic Safety 
 Cardiac safety came into the spotlight in the early 2000s with the downfall of 
Merck’s COX-2 inhibitor Vioxx. Vioxx was approved by the FDA for treatment of acute 
or chronic pain in 1999. It was removed from the market in 2004 due to increased risk of 
heart attack after 18 months. It is estimated that eighty-eight thousand Americans had 
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heart attacks and 38,000 individuals died of cardiovascular related causes after taking 
Vioxx.26,27 It should be noted that these deaths were not confirmed to be from Vioxx. 
Following the events with Vioxx, the FDA started to demand more stringent 
cardiac safety monitoring by sponsors. In October 2005, the FDA required Bristol-Myers 
Squibb and Merck to submit more detailed safety data before approving their new 
diabetes treatment Pargluva. The previous month, an advisory committee voted eight to 
one supporting approval of the drug, but the FDA was concerned about data suggesting 
that drug could double cardiac risk. The FDA also changed its internal practices 
surrounding safety monitoring. In the summer of 2005, the FDA created the Drug Safety 
Oversight Board which “advises the [Center for Drug Evaluation and Research] Director 
on the handling and communicating of important and often emerging drug safety 
issues.”28 An independent review of FDA post-marketing monitoring procedures was also 
conducted in late 2005.   
 Oncologic safety monitoring is less established than cardiac safety monitoring. 
Drugs may have genotoxic and/or non-genotoxic carcinogenic effects that are not 
immediately apparent, and many cancers have long minimum latency periods: 
approximately 2.5 years for thyroid cancer, 4 years for solid cancer, and 11 years for 
mesothelioma.29,30 The typical phase 3 clinical trial runs between one and four years, 
which is an insufficient amount of time to detect a cancer that may have developed 
during the study.31 
Long term follow-up and post-marketing safety studies are essential to capturing 
malignancy events. Adjudication for a multiprotocol drug program can assist in collecting 
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and assessing this oncology data in a standardized, independent, and consistent manner 
over time. Long term longitudinal follow up facilitates pattern recognition and can 
determine both temporal and causal relationships. Data collected over time increases 
validity and succinct results.32,33  
Per the United States Centers for Disease Control and Prevention (CDC), chronic 
diseases are responsible for 70% of deaths each year and treating them accounts for 86% 
of the United States’ health care expenditures.34 In 2012, the top five therapeutic classes 
of prescribed drugs were metabolic agents, central nervous system agents, cardiovascular 
agents, psychotherapeutic agents, and respiratory agents .35 Diabetes (9.2% of Americans 
in 2014), chronic pain (30.7% of adult Americans in 2010), symptoms of coronary heart 
disease (6.0% of adult Americans in 2010), depression (6.7% of adult Americans in 
2016), and chronic obstructive pulmonary disease (COPD) (6.3% of adult Americans in 
2012) are chronic conditions treated by these drugs.35,36,37,38,39,40,41 Cancer is a comorbid 
condition with all the chronic ailments listed above except for chronic pain.42 Chronic 
diseases often require long term medication prescription to manage symptoms. The 
relationship between duration of the condition, time spent on medication treating that 
condition, and the possible development of cancer requires long term observation and 
monitoring.  
 In the early 1990’s the Women’s Health Initiative (WHI) conducted a long-term 
hormone therapy study of post-menopausal women and monitored incidence of breast 
cancer as a primary endpoint. At the time, many post-menopausal women took hormone 
replacement therapy for extended periods to treat symptoms of menopause. Post-
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menopausal women with a uterus received conjugated equine estrogens (CEE) plus 
medroxyprogesterone acetate (MPA) therapy. Post-menopausal women that had 
undergone a hysterectomy received CEE only (placebo). After a mean follow up of 5.2 
years, the trial ended with 199 cases of breast cancer in the CEE+MPA group and 150 in 
the CEE only group.43 Women in the CEE+MPA group had an approximately 4% greater 
risk of breast abnormalities detected on a mammogram after one year on therapy and an 
approximately 11% greater risk after five years than women on CEE only. The 
CEE+MPA group also had significantly more abnormal breast abnormalities detected 
after one-year post intervention cessation than the CEE only group. After one year 
however, the differences between the two groups became statistically insignificant. 44,45  
The long-term observations in this trial exemplify the complex and unclear nature of the 
relationship between cancer, intervention, and existing conditions.     
Histopathology 
 Cancer can be detected by blood tests and imaging, but in most cases a biopsy is 
the only method to obtain a definitive diagnosis. Tissues are examined for underlying 
pathology or histopathology, which is “the anatomic and physiological deviations from 
the normal that constitute disease or characterize a particular disease” and the study of 
these deviations.46 From a safety perspective, histopathology is especially critical when 
determining whether a person has a benign or malignant process occurring. The more 
specific characteristics of the tumor (topography, histology, behavior, and grade) are also 
essential for determining next steps in terms of treatment.         
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In the paper “Interobserver agreement in grading of colorectal cancers – findings 
from a nationwide web-based survey of histopathologists,” Ian Chandler et al. 
commented on the subjective yet important nature of tumor grading: “Tumour grade 
represents a gestalt of all molecular changes, reflecting aggressiveness, and thereby 
potentially offering considerable potential to delineate subgroups with differing 
prognoses.”47 Paul Speight et al. proposes that “grading must impose artificial categories 
onto what is a diffuse, nonhomogeneous continuum of biological change, with no clear 
boundaries.”48  The lack of a truth standard in histopathology may lead to complicated, 
subjective, and variable outcomes. Adjudication can streamline histopathology data 
through standardization and consistency. 
 There are several studies which demonstrate high variance of histopathologic 
interpretations. In the National Inter-Observer Agreement in Colorectal Cancer (NIACC) 
study (Chandler, et al.), twenty digitized colorectal cancer cases obtained from the 
Institute of Cancer Research Section of Cancer Genetics repository were uploaded to a 
dedicated webpage. Each case had one representative hematoxylin and eosin (H&E) 
stained digitized slide. All United Kingdom (UK) consultant histopathologists in the 
Royal College of Pathologists database were contacted via email to participate in the 
survey. A request was made that only pathologists who report gastrointestinal (GI) 
specimens participate. Participants were instructed to grade the specimens using both a 
two-grade and three-grade system. The three-grade categorized tumors as “well 
differentiated, moderately differentiated, and poorly differentiated.” The two-grade 
system combined well and moderately differentiated tumors into low grade leaving 
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poorly differentiated cases as high grade. One hundred senior pathologists from 59 
teaching and district general hospital trusts in the UK (32% of all UK trusts) assessed all 
twenty slides. After calculating interobserver (also known as interrater) variability using 
Fleiss’s kappa, interobserver agreement was determined to be only fair based upon the 
Fleiss’s kappa categorization scheme.47(p496) 
 Fleiss’s kappa is an adaptation of Cohen’s kappa coefficient (Cohen’s kappa), a 
statistic measuring interrater variability accounting for the possibility that raters guess on 
at least some variables due to uncertainty. Cohen’s kappa can be used to compare 
interrater variability between two raters. Fleiss’s kappa can be used for three or more 
raters. Results for either can be interpreted as follows: 0.01–0.20 as no agreement to 
slight; 0.21–0.40 as fair; 0.41– 0.60 as moderate; 0.61–0.80 as substantial; and 0.81–1.00 
as nearly perfect agreement. Confidence intervals should be calculated for the kappa 
statistic because it is an estimate, not a direct measure.49  
 The overall kappa value for both the three-grade specimen coding system and the 
two-grade specimen coding system indicated fair interobserver agreement: 0.351 and 
0.358, respectively. No confidence intervals were provided but the p-value for both 
groups was P<0.0001, indicating that the results were statistically significant.47(p496) Per 
Chandler, et al.: “This national survey…was prompted by anecdotal experience that there 
is a great deal of interpersonal variation in how this seemingly straightforward task is 
performed… [this study] implies that the main difficulty that pathologists face is dividing 
moderately from poorly differentiated tumours. This is an important distinction from the 
point of view of patient management, as this is the most clinically relevant division to 
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make. In addition, in multicenter trials in which patients’ tumors are pathologically 
reported in multiple hospitals, outcome data will not be comparable if the grades 
allocated to tumours suffer high interobserver variation.”47(p497) 
  A substantial or nearly perfect kappa can still be problematic. 765 women at the 
University of Halle had core biopsies of the breast performed between 2006 and 2008. 
Only the first biopsy of each woman was considered in this study. Three pathologists 
specializing in breast cancer reviewed the H&E stained slides and case report form (CRF) 
for each biopsy. The CRF included information regarding age, localization of biopsy, 
number of biopsy cores, microcalcification, and a description of the focus. If x-ray 
images were available those were also provided. Pathologists were instructed to 
categorize the biopsies per the five-level B-categorization scheme suggested by the 
European guidelines for quality assurance in mammography screening (B1: normal or 
uninterpretable; B2: benign; B3: benign but of uncertain biological potential; B4: 
suspicious of malignancy; and B5: malignant including in situ and invasive cancer). 
Categories B1-B2 usually do not require additional testing unless the biopsy is 
uninterpretable or determined not to be representative of the lesion, while categories B3-
B5 usually require invasive work-up.50  
 Pathologist 1 was the local pathologist from the University of Halle. If needed, 
Immunohistochemical (IHC) stained slides could be requested to supplement the H&E 
stained slides already provided. A reference pathologist at the University of Münster 
reviewed the same materials as Pathologist 1. The reference pathologist could also 
request additional IHC stained slides. Discrepancies in assessments were resolved over 
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electronically via digital slide exchange. A third pathologist from Hamburg (pathologist 
2) reviewed the same information as pathologist 1, including IHC stained slides.50 (p941)  
 Interobserver agreement between pathologist 1 and 2 was calculated using 
Cohen’s kappa statistic. The observed kappa based on the five-level categorization was 
0.87 (95% confidence interval (CI): 0.84-0.89). The observed kappa based on the two-
level categorization (B1-B2 vs B3-B5) was 0.93 (95% CI: 0.91-0.95). Both indicate 
almost perfect agreement. There were 103 total histopathological diagnosis discrepancies, 
representing 13.5% of all samples. Forty-nine and a half percent of discrepancies (51 of 
103 cases), however, were clinically relevant disagreements (B1-B2 vs B3-B5). In total, 
7% of women would have been at risk for negative effects from misdiagnosis. Observed 
kappa scores of specific histology results were much lower than those for the 
categorization schemes.50(p943) Adjudication of histopathology samples could potentially 
decrease interobserver variability through decreasing the number of pathologists making 
assessments, sub-specialization of committee members, and standardized 
training/monitoring.  
Case Study: “Interobserver agreement in dysplasia grading: toward an enhanced 
gold standard for clinical pathology trials” (Speight, et al.) 
 
 A 2015 study conducted by Speight et al. sought to establish a gold standard for 
clinical pathology trials using adjudication. This trial focused on dysplasia grading of 
cancers of the lip, oral cavity, and oropharynx, although its results can be extrapolated to 
other types of cancers.  
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 The adjudication committee was comprised of four senior oral and maxillofacial 
pathologists (reviewers). Oral scalpel biopsies from 846 patients comprised the dataset: 
774 subjects with potentially oral malignant disorders and 72 patients with oral squamous 
cell carcinomas. The goal of the adjudication committee was to accurately categorize 
each case into one of seven microscopic diagnostic categories based on the 2005 World 
Health Organization (WHO) guidelines for cancer and precancer of the oral mucosa. The 
exact terminology and their microscopic definitions were agreed upon in advance by the 
adjudication committee. No additional training or calibration was performed. The read 
paradigm is below.48(p477)  
 
Figure 1:Flow chart illustrating the process for the enhanced gold standard 
adjudication sequence.48(p478) 
 Two reviewers from different clinical centers assessed each case (reviewer A and 
reviewer B). The reviewers were also independent from the sites were the biopsies were 
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originally collected. Each reviewer received a unique set of H&E stained slides (adjacent 
serial sections approximately 5 μm apart) and the diagnostic slide used for patient 
management. Reviewers were blinded to all clinical and microscopic findings, 
impressions, and diagnoses from the sites. They were also blinded to the topographical 
location of the lesion.48(p477)   
 If reviewer A and reviewer B agreed on a diagnosis, the shared diagnosis was 
considered final. If reviewer A and reviewer B disagreed, a third reviewer (the 
adjudicator) reviewed the slides from both reviewer A and B. Only one reviewer acted as 
adjudicator; selection of the adjudicator was based on expertise. The adjudicator was 
blinded to the same information as reviewers A and B as well as to their assessments. If 
the adjudicator’s diagnosis was the same as either reviewer A or B, this was considered 
the final diagnosis. When the adjudicator did not agree with either reviewer A or B, a 
consensus meeting between all three reviewers (A, B, and the adjudicator) was held. The 
group reviewed the slides together and was blinded to all previous assessments and site 
data. All cases classified as moderate dysplasia underwent consensus review to further 
categorize the samples into high or low risk cases. Kappa scores were calculated for each 
pair of reviewers and ranged from 0.251 to 0.706. See table from Speight, et al. below. 
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Table 1: Agreement reviewing pathologists during initial review stage; initial review 
stage percent agreement and kappa values shown for individual pathologist 
pairs.48(p479) 
 
 
Reviewers A and B agreed on a diagnosis in 69.9% of cases. An additional 22.8% of 
cases reached a final diagnosis after adjudication. Only 7.3% of cases required consensus 
review, after which 100% of cases had a final diagnosis.48(p479) 
 The adjudication model chosen by Speight, et al. was based a social theory on 
collective decision making postulated by James Surowiecki in his book The Wisdom of 
Crowds. Surowiecki states that a successful crowd wisdom requires diversity of opinion, 
independence of opinion, decentralization (ability to specialize), and aggregation 
(mechanism to consider individual judgements to make a collective decision).51 Speight, 
et al. suggested that by increasing interobserver agreement, the collective decision of 
multiple pathologists might lead to more clinically accurate microscopic diagnoses.48(p481)  
 Measuring “correctness” in diagnosing histopathology samples is impossible 
because the “true” diagnosis is unknown (lack of a truth standard). Using probability 
theory and overall level of agreement and disagreement between reviewers A and B, 
Speight et al. also provided a mathematical basis for the chosen adjudication model. The 
study team calculated probabilities of correct and incorrect diagnoses for six scenarios. 
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The calculations depended on the following assumptions: “(1) all reviewers had an equal 
probability of misdiagnosis that was not influenced by the other reviewers; (2) each slide 
had an equal probability of misdiagnosis; and (3) where 2 reviewers disagree on a 
particular diagnosis, one was assumed correct and the other was assumed 
incorrect”.48(p479) Speight, et. al. recognized the possibility that both reviewers could be 
incorrect, but the assumption that one was correct and the other was incorrect was 
necessary for this derivation. The total probability of correct diagnosis for this study was 
91%. See the table below for all results. The details of the derivation provided in the 
supplementary materials of Speight, et. al. can be found in the appendix. The results of 
Speight’s probability calculations are in Table 2. 
Table 2: Probability of correct 7-level diagnosis (normal, benign, dysplastic mild, 
dysplastic moderate, dysplastic severe, dysplastic carcinoma in situ, malignant) with 
2 reviewers and use of an adjudicator when the 2 reviewers disagree.48(p479) 
 
 Based on the results in the table above, Speight calculated that the probability of 
correct diagnosis in his study was 91%. The study conducted by Speight, et al. provides a 
framework onto which further studies of the effectiveness of adjudication in 
histopathology can be based. The read paradigm is easy to implement and is well-
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supported by group psychology. The claim that adjudication is reliable and accurate is 
substantiated with a convincing probability theory.  
Thesis 
 
 The aim of this paper is twofold: (1) to demonstrate an overall need for 
adjudication of histopathology related outcomes in clinical trials through quantifying 
interrater variability using kappa scores and percent agreement, and (2) to demonstrate 
that potential malignancies other than oral dysplasia could similarly benefit from 
adjudication – to include, among others, dermatology, gynecology, genitourinary, and 
gastroenterology. In reviewing whether adjudication can effectively benefit a variety of 
pathology sub-specialties, it would need to be established that there is significant 
interrater variability. To examine whether such variability is present, local diagnoses will 
be compared with independent diagnoses to find any contrasts and disparities between the 
results.  
 The following discrepancies in diagnoses will be assessed: neoplasm vs non-
neoplasm; discrepancies in malignant vs benign processes, discrepancies in morphology, 
and discrepancies in classifications that would lead to different courses of treatment for 
the subject (cases not similar). These analyses will be performed on the dataset as a 
whole, within each pathology sub-specialty, and between non-melanoma skin cancers 
(NMSC) and other malignancies (a clinically significant difference based on patient risk).   
 If it is the case that there are clinically significant discrepancies between local and 
central diagnoses and that central adjudication yields more accurate diagnoses than a 
local pathologist, then it should also be accepted that adjudication ought to be more 
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widely used in clinical trials to assess histopathology-related safety outcomes and 
endpoints.   
 
METHODS 
 This is a retrospective cross-sectional study assessing interrater variability 
between local and central diagnoses of biopsy samples in a clinical trial setting. Certified 
Professional Coders (CPC) and central pathologists used the International Classification 
of Diseases for Oncology revision 3 (ICD-O 3) to codify the local and central 
assessments to permit comparison. Samples included in this analysis were collected as 
part of an industry sponsored global adjudication program managed by a contract 
research organization (CRO). The CRO was responsible for identification of potential 
malignancy events, collection and processing of specimens, generation of study 
documents, and independent reviewer selection, training, management, and monitoring. 
The sponsor approved the potential event identification criteria, the charter, and the 
electronic case report forms (eCRFs). Specimens included in this dataset were assessed 
between January 7, 2015 and March 15, 2017.  
International Classification of Diseases for Oncology 
 This study used the International Classification of Diseases for Oncology Version 
3, or ICD-O 3, to describe both local and central diagnoses. ICD-O is a standardized 
coding system developed by the World Health Organization (WHO) to classify site 
(topography), histology, behavior, and grade of abnormal tissue growths (neoplasms). 
Developed in 1976, it is used primarily in tumor and cancer registries. ICD-O is based on 
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the American Cancer Society’s Manual of Tumor Nomenclature and Coding 
(MOTNAC), which was first published in in 1951.52 The WHO stresses that “ICD-O is a 
coded nomenclature and not a classification scheme for neoplasms; the listing of terms 
from different classifications does not represent endorsement of any particular one.”53 
Topography codes are four-character codes; the first character is always “C” and 
the next three characters are always numbers. The first two numbers indicate site and the 
number after the decimal indicates a more specific sub-site.  
 
 
 
Figure 2: ICD-O Topography Code.53 
Topography codes run from C00.0 to C80.9. They are closely related to those in 
the 10th revision of the International Statistical Classification of Diseases and Related 
Health Problems (ICD-10).54 The ICD-O topography list allows for greater site 
specification for non-malignant tumors and provides topography codes for 
haematopoietic and reticuloendothelial tumors, which ICD-10 does not cover.54  
 The histology and behavior codes represent the morphology (microscopic 
features) of a neoplasm. The codes start with the letter “M” and are followed by five 
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numbers which range from M-8000/0 to M-9992/3. The first four digits are the histology 
code and the number after the slash is the behavior code. The table below explains 
possible behavior code values and their definitions (Table 3).  
Table 3: ICD-O Behavior Codes.53 
Code Definition 
/0 Benign 
/1 Uncertain, whether benign or malignant 
    Borderline malignancy 
    Low malignant potential 
    Uncertain malignant potential 
/2 Carcinoma in situ 
   Intraepithelial 
   Noninfiltrating 
   Noninvasive 
/3 Malignant, primary site 
/6 Malignant, metastatic site 
   Malignant, secondary site 
/9 Malignant, NOS - uncertain whether primary or 
metastatic site 
 
 The second digit after the slash (M0000/00) describes the grade or differentiation 
of a neoplasm (Table 4). It also represents the immunophenotype designation for 
lymphomas and leukemias (Table 5).   
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Table 4: ICD-O Histologic Grading and Differentiation Codes.53 
Code Grade Definition 
1 I Well differentiated 
   Differentiated, NOS 
2 II Moderately differentiated  
   Moderately well differentiated 
   Intermediate differentiation 
3 III Poorly differentiated  
4 IV Undifferentiated 
    Anaplastic 
9 Grade or differentiation not determined, not stated 
or not applicable 
 
Table 5: ICD-O Immunophenotype Designation for Lymphomas and Leukemias.53 
Code Definition 
5 T-cell 
6 B-cell  
   Pre-B  
   B-precursor 
7 Null cell  
   Non T-non B 
8 Natural killer (NK) cell 
9 Cell type not determined, not stated or not 
applicable 
 
A complete ICD-O code for one neoplasm will have eleven characters representing 
topography (four), histology (five), behavior (one), and grade, differentiation, or 
immunophenotyped (lymphomas and leukemias only) (one).  
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Histology Grading
Behavior
 
Figure 3: ICD-O Complete Code.53 
 
Adjudication Committee and Certified Professional Coders (CPC) 
  The CRO leveraged an existing relationship with a Boston, Massachusetts 
medical facility to create the adjudication committee, which independently assessed 
tissue samples for this study. A senior member of the pathology department, the “lead 
pathologist,” worked with the CRO to create the adjudication committee in November 
2014. The original adjudication committee consisted of seven members including the lead 
pathologist; the committee as of March 2017 had expanded to thirteen members including 
the lead pathologist. The March 2017 committee had five of the original seven members 
and eight additional members that were added between February 2016 and November 
2016 to keep up with an increasing workload. The lead pathologist left the committee in 
June 2016; he selected his own replacement as one of the other original six original 
members. One of the other original members was removed in September 2016 due to 
declining performance identified during reviewer performance monitoring. In cases 
where this pathologist had made the final diagnosis, or “authoritative review,” a data 
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integrity assessment was performed. No outliers or data integrity risk was identified.  
Fourteen pathologists were the authoritative reviewer on a case at least once.  
 All committee members were United States board certified pathologists licensed 
to work in the United States. Committee members had a wide variety of educational and 
professional backgrounds both within and outside of the United States, which contributed 
to the independent of opinion of each reader. All except one were full time faculty 
members at the Boston medical facility. The outlier was a pathology fellow selected by 
the lead pathologist as committee member based on performance. The pathology fellow 
did not perform any authoritative reviews.  
 Committee members were divided into sub-specialty reading groups by the lead 
pathologist. Not all sub-specialty group members were specialists in the field, but per the 
lead pathologist had enough experience to assess cases in that group. If a case required 
adjudication (the diagnoses from pathologist 1 and 2 did not match), the “tie-breaker” 
(adjudicator or PR3) in each sub-specialty group was either a practicing specialist in the 
field or, if no specialist was available, the lead pathologist or designee selected by the 
lead pathologist. The lead pathologist also had the authority to reassign committee 
members to sub-specialty groups as needed.      
 Two certified professional coders (CPC) were part of the review team, although 
not committee members. The CPCs received the local pathology reports (LPR) from the 
sites and coded the local diagnosis for the biopsy per ICD-O 3. The CPCs did not 
perform any independent reviews for this study.   
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 Pathology fellows selected by the lead pathologist provided auxiliary services 
when needed, such as identifying stains when they were not specified by the site. 
Biopsied tissue is usually transparent when put on a slide; staining with certain chemicals 
assists pathologists with viewing tissue structure and certain cell types.55 When a local 
lab report describing multiple biopsies was received and slides were received without 
labels, the pathology fellows attempted to match the provided slides to the biopsies on the 
lab report. Pathology fellows, except for one (see above) did not perform any reviews.  
All pathology reviewers, pathology fellows, and CPCs were blinded to the 
identity of the sponsor, investigational product, and protected health information (PHI). 
Charter and Independent Review Manuals 
The charter outlined the process for collecting and processing source materials 
from the sites, definitions and explanations of terms relevant to making an assessment, 
minimum requirements for making assessments/how to handle cases that do not meet the 
minimum requirements, eCRF description, committee membership, training, testing 
requirements, read paradigm, and bias minimization plan.11(p59),12 Pathology reviewers 
(committee members) were trained on the charter and the independent review manual. 
The CPCs were trained on the charter and the CPC-specific review manual. Pathology 
fellows were not required to be trained on the charter or review manuals, but attended an 
orientation covering the project goals and services required.  
The adjudication program had three charter revisions since the initial version 
came into effect in November 2014. Changes between each charter revision, effective 
date, and whether re-training of committee members was required is documented in the 
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table below. Reviewers that were not part of the original adjudication committee were 
trained on the latest version of the charter at the time that they joined (Table 6).   
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Table 6: Charter revisions and training requirements. 
Version Changes from previous version 
Effective 
Date 
Training 
required for 
committee 
members? 
1.0 N/A Initial Release 
10-Nov-
14 
Yes – Initial 
Release 
2.0 
• Updated sponsor/CRO roles and responsibilities 
• Updated committee membership 
26-May-
15 
No – 
changes do 
not affect 
review 
process 
3.0 • Removed draft versions from revision history  
• Updated committee membership 
22-Dec-
15 
No – 
changes do 
not affect 
review 
process 
4.0 
• Added review process for photomicrographs 
• Clarified blinding procedures 
• Removed reference to sponsor approval for reviewer 
manuals per latest SOP update 
• Updated requirement for sponsor signatures on User 
Requirements to only when sponsor facing changes 
are made 
• Added Potential Primary Event notifications as 
method to receive information regarding potential 
malignancy events 
• Added digital pathology process for sites in China 
• Clarified processes regarding multiple biopsies 
received for one malignancy event 
• Updated operational workflow diagram 
• Added histopathology processing as a workflow step 
(not a process change, just needed to be 
documented) 
• Updated assessment workflow diagram 
• Added assessment of EBV status for lymphoma 
cases 
• Removed turnaround time requirements 
• Clarified PR3 role 
• Added requirement for comments when 
similarity assessment = no 
• Added definitions for slide image/quality 
• Updated adjudication criteria 
• Committee member updates 
• Updated data management section 
• Updated close out details 
• Updated sponsor clinician review process 
• Removed requirement of U.S. medical licenses and 
board certifications for reviewers (physicians 
certified outside of the U.S. permitted) 
22-Jun-16 
Yes – 
changes in 
bold may 
affect review 
process 
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 This program had separate manuals for CPCs and independent reviewers. Both 
included information regarding how to access/navigate the electronic review system and 
how to complete the eCRF based on the rules in the charter. Both the CPC manual and 
reviewer manual underwent one revision since the original documents were created. 
Updates made in both documents in each revision as well as training requirements are 
outlined below in Table 7. Version 1.0 of both the CPC and reviewer manuals were 
reviewed and approved by the sponsor. Due to a standard operating procedures (SOP) 
update at the CRO, Version 2.0 of both documents was not required to be reviewed or 
approved by the sponsor. Reviewers that were not part of the original adjudication 
committee were trained on the latest version of the appropriate manual at the time that 
they joined.  
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Table 7: Review manuals revisions and training requirements. 
 
Version Changes from previous version 
Effective 
Date 
Training 
required for 
committee 
members? 
1.0 N/A Initial Release 
15-Dec-14 
– CPC 
Manual 
 
17-Dec-14 
– 
Reviewer 
Manual 
Yes – Initial 
Release 
2.0 
• Removed duplicate information already in charter 
• Referenced newly added info buttons regarding 
neoplasm versus non-neoplasm definitions on 
eCRF 
• Clarified instructions regarding histology and 
behavior code selection 
• Added instructions for download and assessment 
of photomicrographs (Reviewer Manual only) 
• Added instructions for review of EBV stained 
slides for lymphoma cases (Reviewer Manual 
only) 
16-Aug-
16 
Yes – 
changes in 
bold may 
affect review 
process 
 
Histopathology Assessments 
 Sites were instructed to submit the slides used to make the local diagnosis 
(diagnostic slides) and/or the block from which the diagnostic slides were cut. Tissue 
samples were categorized into sub-specialties based on the anatomic location of the 
biopsy and Medical Dictionary for Regulatory Activities (MedDRA1®) preferred term of 
the potential malignancy event. MedDRA® is a medical terminology dictionary to 
facilitate international sharing of regulatory information for medical products used by 
                                                        
1 MedDRA® the Medical Dictionary for Regulatory Activities terminology is the international medical 
terminology developed under the auspices of the International Conference on Harmonisation of Technical 
Requirements for Registration of Pharmaceuticals for Human Use (ICH); MedDRA® trademark is owned 
by IFPMA on behalf of ICH. 
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humans.56 The dictionary is hierarchized, with the preferred term being “a distinct 
descriptor (single medical concept) for a symptom, sign, disease diagnosis, therapeutic 
indication, investigation, surgical or medical procedure, and medical social or family 
history characteristic.”57 The sub-specialty pathology categories were: breast, skin 
(dermatology), ear/nose/throat (ENT), gastrointestinal tract (GI), gynecology (GYN), 
genitourinary tract (GU), lung, intradural, lymphoma, sarcoma, and cytology.  
Samples were delivered to a sub-specialty committee pathologist by a CRO staff 
member. The staff member remained with the pathologist until the read was complete to 
ensure independent was maintained throughout the read and then returned with the slides 
to the CRO office. Each sample was assessed on a separate eCRF. Pathologists had no 
information regarding relationships between biopsies, number of biopsies per potential 
malignancy event, or potential malignancy event MedDRA® terms. They were blinded to 
the entire LPR, including local diagnosis. Pathologists had access to the following 
information for each case (if available): biopsy date, biopsy type and details if “other” 
was selected, anatomic location and details if “other” was selected, number of blocks 
provided, number of slides provided, and stain types. This is similar to the information 
provided to the pathologists in Speight’s study. Anatomic location was not available to 
pathologists in Speight’s study. The study however was specific to oral cancers so 
specific location may not have been necessary.48(p477) Pathologists were also informed of 
the CRO provided sample identification number to corroborate against the slide case 
labels and slide labels to ensure the cases were read on the appropriate eCRFs.  
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The pathologists were required to assess slide quality and degree of confidence 
for all cases. Options for slide quality were Good (the technical quality allows 
appropriate diagnostic interpretation); Fair (the technical quality is not optimal but does 
not limit the diagnostic interpretation); Poor (the technical quality is sub-optimal and 
limits the diagnostic interpretation); and Unevaluable (the technical quality is sub-optimal 
and precludes the diagnostic interpretation). Comments regarding slide quality were 
optional except when degree of confidence was indicated as low. Pathologists could 
request additional staining if necessary to make an assessment.  
For each sample, pathologists were required to determine whether it was a 
neoplasm (abnormal tissue growth resulting from uncontrolled cell division (and/or lack 
of cell death) or non-neoplasm (abnormal tissue growth, reactive, inflammatory, or 
hamartomatous in origin). ICD-O 3 only codes neoplasms, so samples assessed as non-
neoplasm did not require any further evaluation. Neoplastic samples had topography, 
histology, behavior, and grade or immunophenotype coded per ICD-O 3. Epstein Barr 
Virus (EBV) status was assessed for samples assessed as lymphoma.  
The local diagnosis for each sample was provided to one of two CPCs on a LPR. 
Each sample was assessed on a separate eCRF, independent of those used by the 
pathologists. For neoplasms, the CPCs categorized samples as neoplasm or non-
neoplasm. If the case was categorized as a neoplasm, the CPC entered topography, 
histology, behavior, and grade or immunophenotype for the biopsy and associated 
diagnosis using ICD-O 3. Comments regarding were optional. The CPCs had no access to 
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the tissue samples and could not request additional information. CPCs did not assess slide 
quality or provide degree of confidence assessments.   
Read Paradigm 
 In the first round of reviews, each local diagnosis on the provided LPR was 
categorized and coded (if a neoplasm) by a CPC. All other information on the LPR was 
used as a reference only. Concurrently, each sample was assessed by a pathologist (PR1) 
in the sub-specialty reading group to which it pertained based on anatomic location and 
MedDRA® preferred term. CPCs and pathologists had no interaction with each other at 
any point in the review process. If the categorization as neoplasm or non-neoplasm and 
the ICD-O 3 code selection (if neoplasm) by the CPC and the pathologist were identical, 
the shared assessment was considered the final diagnosis. No further reads occurred. 
 If the assessments by the CPC and PR1 did not match, the tissue sample was 
assessed by a second pathologist (PR2) in the same sub-specialty reading group. The PR1 
and PR2 diagnoses were compared. If they were the same, no further reads occurred; the 
central diagnosis decided by PR2 was the authoritative review. PR2 was then provided 
the LPR with the local diagnosis, the CPC assigned categorization of neoplasm or non-
neoplasm, and the CPC selected ICD-O 3 code (neoplasms only). PR2 compared his/her 
assessment and the CPC assessment to determine whether the diagnoses were similar 
even though exact categorization and/or codes were different. Similar was defined as 
similar morphology where the patient management and treatment would be comparable.  
 If the PR2 and PR1 assessments did not match, then the tissue sample was read by 
a third pathologist (PR3) in the same sub-specialty reading group.  The third pathologist’s 
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assessment was always considered the final and authoritative read. After the final 
assessment on the sample was made, PR3 was provided the LPR with the local diagnosis, 
the CPC assigned categorization of neoplasm or non-neoplasm, and the CPC selected 
ICD-O 3 code (neoplasms only). Like PR2, PR3 indicated whether the CPC coded 
diagnosis and the final central diagnosis were similar per the definition above. The read 
paradigm is outlined in Figure 4.   
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Figure 4: Read Paradigm. 
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Follow Up Use of Histopathology Results 
The final local and central diagnoses for each histopathology sample were 
provided to a separate oncology adjudication committee. The histopathology information 
was part of a subject dossier that included clinical information such as consultation 
reports, discharge summaries, clinical notes, lab reports, and medical history records 
relating to the potential malignancy event. Histopathology samples representative of the 
same potential malignancy event were grouped together into one dossier. The oncology 
adjudication committee then made an overall assessment regarding the event.  
The sponsor was interested in assessing differences between two important 
clinical classes: non-melanoma skin cancers (NMSC) and all other malignant processes. 
Although both classes represent malignant processes, the significant differences between 
them are important from a safety perspective. The two most represented non-melanoma 
skin cancers are basal cell carcinoma and squamous cell carcinoma. Approximately three 
million people in the United States are diagnosed with non-melanoma skin cancer each 
year. Only about two thousand people in the United States die from non-melanoma skin 
cancers each year, making death from these cancers uncommon. The highest risk factor 
for non-melanoma skin cancers is sun exposure; other risk factors, such as increasing age 
and light-colored skin, are related to sun exposure. These cancers can be prevented and 
managed through limiting exposure to sun, skin screenings, and removal of suspicious 
lesions as soon as they are identified.58  
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Cancers that are not non-melanoma skins cancers tend to be harder to treat, have 
higher mortality rates, and are more serious safety concerns than non-melanoma skin 
cancers. For example, melanoma accounts for only about 1% of all skin cancers but has 
an approximate mortality rate of 11%.  The mortality rate for basal and squamous cell 
carcinomas, which make up 80% of all skin cancers, is less than 0.01%.58,59 The age-
adjusted five-year survival rates for cancers other than non-melanoma skin cancers range 
from 98% (testicular cancer) to 3% (pancreatic cancer).  The average age adjusted five-
year survival rate for cancers other than non-melanoma skin cancers is about 54%.60 
 
Statistical Analysis 
 The raw dataset was obtained from the CRO managing the adjudication program. 
The original file was in Excel format. All sponsor and CRO-specific identifiers and 
personal information for pathologists and CPCs were blinded before analysis. 
 Local and central diagnoses of the cases were compared to assess interrater 
variability. The table below outline the categories for inter-read comparison (Table 8).  
Table 8: Analysis categories for interrater variability comparison. 
 
Analysis Description 
1 Neoplasm versus Non-Neoplasm 
2 Benign versus Malignant 
3 Discrepancies in Morphology 
4 
All discrepancies leading to differences in treatment (cases NOT similar), 
including those identified in categories 1, 2, and 3 
 
Knowing whether a sample is a neoplasm or non-neoplasm is the first step to determining 
whether a malignancy is possible (analysis 1). Neoplasms can become malignant whereas 
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non-neoplasms usually do not. From a safety perspective, analysis 2 (benign versus 
malignant) is the most important. Not only could misclassification potentially lead to an 
inaccurate risk profile for the drug under investigation, but could result in serious and 
often life-threatening consequences for subjects. Analysis 2 will be performed under two 
sets of circumstances; in the first (2.1), all cases in the dataset will be taken into 
consideration. In the second (2.2), all non-neoplasms will be removed. Under 2.1, non-
neoplasms will be considered benign. Under both 2.1 and 2.2, behavior codes of /0 and /1 
will be considered benign; all other behavior codes will be considered malignant. The 
effects of discrepancies in morphology (analysis 3) could be negligible if the subject 
would be treated the same regardless of whether the local or central diagnosis was used. 
However, knowing more specific information about potential malignancies can elucidate 
areas of safety concern that require further and/or more specialized subject monitoring. 
Otherwise the differences could be significant. Analysis 3 will be performed under two 
sets of circumstances; in the first (3.1), all cases in the dataset will be taken into 
consideration. In the second (3.2), all non-neoplasms will be removed. Analysis 4 will 
capture all cases where the authoritative pathologist indicated that the local and central 
diagnoses were not similar (i.e. different courses of treatment would be taken for one 
versus the other). Analysis 4 will be performed under two sets of circumstances. In the 
first (4.1), all cases in the dataset will be included (where a similarity assessment did not 
occur (when the local ICD-O code matched with the ICD-O code selected by PR1) will 
be considered similar). In the second (4.2), all round 1 agreements will be removed and 
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only cases that had a similarity assessment (cases that were assessed by PR2 and/or PR3) 
will be analyzed.     
The statistical sub-groups are in Table 9. Each sub-group was analyzed per all 
categories in Table 8. The statistical sub-groups were designed to illuminate potential 
differences in types of discrepancies seen in each.  
Table 9: Statistical Sub-Groups. 
 
Group Description 
A Overall dataset (all cases) 
B 
Individual Pathology Sub-Specialty Reading Groups (breast, skin 
(dermatology), ear/nose/throat (ENT), GI, gynecology (GYN), GU, lung, 
intradural, lymphoma, sarcoma, and cytology) 
C 
Non-melanoma skin cancers (NMSC) versus all other malignant processes (non-
NMSC or “other”) 
 
 Interrater variability will be measured using Cohen’s kappa coefficient/statistic 
(referred to as “kappa” or “kappa score” in later sections) and percent agreement. 
Cohen’s kappa is based on the chi-square table in statistics and measures interrater 
variability between two raters while accounting for the possibility that raters guess on at 
least some variables due to uncertainty. Percent agreement is easier to calculate than 
Cohen’s kappa (number of differences between local and central diagnoses divided by the 
sum of the cases in each analysis), but the possibility of guesswork is not taken into 
account.49(p3) Many references recommend 80% agreement as the most common 
minimum acceptable percent agreement when used in a healthcare setting. Percent 
agreement under 80% could be indicative of inconsistencies in assessments. The formula 
for Cohen’s kappa is kappa = (p0 – pe)/(1-pe) where p0 is the relative observed agreement 
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among raters and pe is the hypothetical probability of chance agreement. 49(p5),61 Results 
range between 0.01 and 1.00 with 0.01–0.20 as no agreement to slight; 0.21–0.40 as fair; 
0.41– 0.60 as moderate; 0.61–0.80 as substantial; and 0.81–1.00 as nearly perfect 
agreement. Confidence intervals should be calculated for the kappa statistic because it is 
an estimate, not a direct measure.49(p7) For this study a 95% confidence interval will be 
used. P-values will also be noted (p<0.05 considered statistically significant). Statistics 
were generated using R x64 3.3.1.  
RESULTS 
The sample size flow chart is in Figure 5. The original dataset had 1,063 cases 
assessed between January 7, 2015 and March 15, 2017. Four hundred two cases did not 
have any tissue samples provided, leaving 661 with biopsy samples available for central 
assessment. Photomicrographs were substituted for physical tissue samples in one case; 
this case was removed from the analysis. All cases with either poor or unevaluable slide 
quality were omitted from the dataset (41 cases). Cases for which additional data was 
requested were also removed (17 cases). The final dataset included 602 cases. 
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Figure 5: Study Population Flow Chart. 
 
The analyses performed and their associated identifiers are outlined in Table 10. 
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Table 10: Analysis Legend. 
 
Analysis Code Description 
Analysis 1 Neoplasm versus Non-Neoplasm 
Analysis 2.1 Benign versus Malignant (all cases) 
Analysis 2.2 
Benign versus Malignant (cases assessed as non-neoplasm by the site or authoritative 
central pathologist removed) 
Analysis 3.1 Discrepancies in Morphology (all cases) 
Analysis 3.2 
Discrepancies in Morphology (cases assessed as non-neoplasm by the site or 
authoritative central pathologist removed) 
Analysis 4.1 
All discrepancies leading to differences in treatment (cases NOT similar), including 
those identified in categories 1, 2, and 3 (all cases) 
Analysis 4.2 
All discrepancies leading to differences in treatment (cases NOT similar), including 
those identified in categories 1, 2, and 3 (cases where site and central diagnosis 
matched in the first round of reviews removed) 
 
Results by Statistical Sub-Group 
The interrater variability results for all groups are below. Each table for analyses 
1, 2.1, 2.2, and 3 will include the kappa score, 95% confidence interval and p-value for 
the kappa score, kappa agreement category, percent agreement, and the sample size (N). 
The kappa category qualitatively describes the level of agreement for each analysis. 
Results from analysis 4 will be addressed separately. 
Group A interrater variability results are for analyses 1, 2.1, 2.2, 3.1, and 3.2 in 
Table 11. Group A includes all cases in the dataset.  
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Table 11: Interrater variability results - Group A.2 
 Kappa 
95% 
Confidence 
Interval  P-value 
Kappa 
Category 
Percent 
Agreement N 
Analysis 1 0.81 0.76-0.85 P<0.001 near perfect 90.4 602 
Analysis 
2.1 0.84 0.79-0.88 P<0.001 near perfect 91.9 602 
Analysis 
2.2 0.85 0.75-0.95 P<0.001 near perfect 97.1 309 
Analysis 
3.1 0.59 0.55-0.64 P<0.001 moderate 68.3 602 
Analysis 
3.2 0.52 0.47-0.58 P<0.001 moderate 57.0 309 
 
All results were statistically significant based on confidence intervals and p-values. 
Analyses 1, 2.1 and 2.2 had near perfect kappa agreement with all percent agreements 
over 90%. Analyses 3.1 and 3.2 had moderate kappa agreement with percent agreements 
of 68.3% and 57.0%, respectively. 
When all cases were considered (analysis 4.1), 32% of local diagnoses did not 
match the final central diagnosis and the authoritative central pathologist considered 11% 
of diagnoses not similar. When cases with matching diagnoses in the first round of 
reviewers were removed (analysis 4.2), 95% of local diagnoses did not match the final 
central diagnosis and 34% of diagnoses were not considered similar. Due to an 
application error, ten cases had a similarity assessment incorrectly triggered after the 
authoritative read even though the local and final central diagnosis were the same. These 
                                                        
2 Analysis 1: Overall dataset: neoplasm vs non-neoplasm, Analysis 2.1: benign vs malignant (all 
cases), Analysis 2.2: benign vs malignant (non-neoplasms removed), Analysis 3.1: discrepancies in 
morphology (all cases), Analysis 3.2: discrepancies in morphology (non-neoplasms removed) 
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account for the 5% of cases that had matching local and central diagnoses that underwent 
a similarity assessment.    
 Group B consists of all cases in group A, but separated by sub-specialty reading 
groups (sub-groups). Note that 4 cases were removed from the analysis because they 
could not be clearly categorized into the main sub-specialty reading groups. Tables 12 
(analysis 1), 13 (analyses 2.1 and 2.2), and 14 (analyses 3.1 and 3.2) include the interrater 
variability results for each sub-group. For sub-groups in bold, the upper boundary of the 
confidence interval exceeded 1.00. Sub-groups in italics were not statistically significant 
based on the confidence interval and p value. In all tables, dermatology was the largest 
sub-group. In analyses 1 and 2, all categories except lymphoma had near perfect or 
substantial kappa agreement and percent agreement was above 80% for all categories. In 
table 14, the range of kappa values and percent agreements were wider than in previous 
analyses.  
Table 12: Interrater variability results - Group B Analysis 1.3 
 
                                                        
3 Individual Pathology Sub-Specialty Reading Groups: neoplasm vs non-neoplasm 
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Table 13: Interrater variability results - Group B Analyses 2.1 and 2.2.4 
 
Table 14: Interrater variability results - Group B Analyses 3.1 and 3.2.5 
  
                                                        
4 Individual Pathology Sub-Specialty Reading Groups: Analysis 2.1: benign vs malignant (all cases), 
Analysis 2.2: benign vs malignant (non-neoplasms removed) 
5 Individual Pathology Sub-Specialty Reading Groups: Analysis 3.1: discrepancies in morphology (all 
cases), Analysis 3.2: discrepancies in morphology (non-neoplasms removed) 
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Discrepancies in diagnoses for all sub-groups in category B are summarized in 
Table 15, including those that would lead to differences in treatment. The same 4 cases 
removed in the analyses 1, 2, and 3were removed for the analyses below because they 
could not be clearly categorized into the main sub-specialty reading groups. The 
percentage of dissimilar diagnoses leading to treatment differences varied by sub-group, 
however it is worth nothing that the ENT and lung sub-groups had no discrepancies that 
would lead to any treatment differences.      
Table 15: Discrepancies in diagnosis and treatment - Group B Analyses 4.1 and 4.2.6 
  
Percent Mismatch 
between Local and 
Central Diagnosis 
Percent Dissimilar 
leading to different 
treatments N 
Analysis 4.1 Breast 21 7 29 
 Cytology 33 11 9 
 Dermatology 47 17 253 
 ENT 41 0 17 
 GI 25 5 99 
 GU 6 5 126 
 GYN 36 19 36 
 Lung 18 0 11 
 Lymphoma 30 20 10 
 Sarcoma 62 25 8 
Analysis 4.2 Breast 86 29 7 
 Cytology 100 33 3 
 Dermatology 97 35 122 
 ENT 100 0 7 
 GI 93 19 27 
 GU 89 67 9 
 GYN 93 50 14 
 Lung 100 0 2 
 Lymphoma 100 67 3 
 Sarcoma 100 40 5 
                                                        
6 Individual Pathology Sub-Specialty Reading Groups: Analysis 4.1: All discrepancies leading to 
differences treatment (cases NOT similar), including those identified in categories 1, 2, and 3, 
Analysis 4.2: All discrepancies leading to differences treatment (cases NOT similar), including those 
identified in categories 1, 2, and 3 (round 1 agreements removed) 
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Thirty-two percent of local diagnoses did not match the final central diagnosis. 11% of 
local and central diagnoses were not similar when all cases in group B were considered 
(4.1). When cases with matching diagnoses in the first round of reviews were removed 
(4.2), 95% of local diagnoses did not match the final central diagnosis and 34% were 
considered not similar. The averaged results for both analyses 4.1 and 4.2 for group B are 
logically the same as those for group A, as group A is comprised of all sub-groups.   
The group C (NMSC vs other malignancies (non-NMSC)) interrater variability 
results for analyses 1, 2.1, 2.2, 3.1, and 3.2 are presented in Table 16. Note that 2 cases 
were not included in the analysis because both non-melanoma skin cancer and melanoma 
were provided as diagnoses in at least one round during the review process. Almost all 
categories had near perfect or substantial kappa agreement except in analysis 3.2.  
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Table 16: Interrater variability results - Group C.7 
 
In analysis 4.1, when all NMSC cases were considered, 45% of local diagnoses did not 
match the final central diagnosis and 15% of local and central diagnoses were not 
considered similar. When cases with matching diagnoses in the first round of reviewers 
were removed (4.2), 96% of local diagnoses did not match the final central diagnosis and 
33% were considered not similar. 22% of local diagnoses did not match the final central 
diagnosis and the authoritative central pathologist did not consider 9% similar for non-
NMSC in analysis 4.1. When non-NMSC cases with matching diagnoses in the first 
round of reviewers were removed (4.2), 93% of local diagnoses did not match the final 
central diagnosis and 36% were considered not similar.  
                                                        
7 Non-melanoma skin cancers versus all other malignant processes (non-NMSC): Analysis 1: neoplasm vs 
non-neoplasm, Analysis 2.1: benign vs malignant (all cases), Analysis 2.2: benign vs malignant (non-
neoplasms removed), Analysis 3.1: discrepancies in morphology (all cases), Analysis 3.2: 
discrepancies in morphology(non-neoplasms removed) 
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Results by Analysis  
Figure 6 summarizes the results of analysis 1 (separating specimens between 
neoplasms and non-neoplasms) for all groups. The average kappa score (0.80) and 
percent agreement (90.9%) were the same for group A as well as when the kappa scores 
and percent agreements for all sub-groups when averaged together. All percent 
agreements for analysis 1 surpassed the minimally acceptable agreement rate in a 
healthcare setting of 80%.  
 
Figure 6: Analysis 1 results for all groups. 
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The kappa category distribution is in Figure 7. 
 
Figure 7: Analysis 1 - Kappa categories. 
 
Ninety two percent of sub-groups (all except lymphoma) had either near perfect or 
substantial agreement; the lymphoma sub-group had moderate agreement.  
Analysis 2 assessed interrater variability when determining whether specimens 
were benign or malignant. This distinction is crucial as misdiagnosis could result in 
inaccurate risk profiles and/or grave health consequences for subjects. Figure 8 shows the 
differences in kappa scores when non-neoplasms were (2.1) and were not (2.2) included 
in the analysis.  
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Figure 8: Analyses 2.1 and 2.2 - Benign vs malignant kappa scores for all groups. 
 
A kappa score for the sub-category “breast” could not be calculated using R when non-
neoplasms were removed. The value is assumed to be at least 0.81 (near perfect 
agreement) based on percent agreement; this is the value used in the figure above.  
The group A kappa score when including and not including non-neoplasms was 
0.84 and 0.85, respectively. The average kappa score among all sub-categories when 
including non-neoplasms was 0.83; when excluding non-neoplasms, it was 0.89. All 
kappa scores indicated at least moderate agreement and most displayed substantial to near 
perfect agreement.  
Figure 9 shows percent agreement among raters when assessing whether a sample 
was benign or malignant. All analysis groups were included. 
  
0.5
0.6
0.7
0.8
0.9
1
Benign vs Malignant Kappa Scores
Kappa (all cases) Kappa (non-neoplasms removed)
  56 
 
Figure 9: Analyses 2.1 and 2.2 - Benign vs malignant percent agreement for all 
groups. 
Average percent agreement among sub-groups when including and not including non-
neoplasms was 92.4% and 97.6%, respectively. Both were within 1.5% of the group A 
values (91.9% and 97.1%, respectively). Raters reached the suggested minimally 
acceptable percent agreement in healthcare (80%) in all sub-categories.  
 Kappa scores for discrepancies in morphology codes when non-neoplasms were 
(analysis 3.1) and were not (analysis 3.2) included are in Figure 10. 
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Figure 10: Analyses 3.1 and 3.2 - Discrepancies in morphology kappa scores for all 
groups. 
A kappa score for sub-category lymphoma cases could not be calculated using R when 
non-neoplasms were not included due to sample size.   
 
Kappa scores for this analysis were considerably lower than those in previous analyses. 
The group A kappa score was 0.59 when including non-neoplasms and 0.52 when they 
were removed. The average kappa score for all sub-categories when including non-
neoplasms was 0.56; when excluding non-neoplasms, it was 0.44.  
 Figure 11 shows percent agreement in morphology when non-neoplasms were and 
were not included. 
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Figure 11: Analyses 3.1 and 3.2 - Discrepancies in morphology percent agreement 
for all groups. 
 
The average percent agreement was 67.7% when including non-neoplasms and 56.1% 
when excluding non-neoplasms.  
 Kappa agreement categories for analyses 2.1, 2.2, 3.1, and 3.2 are presented in 
Figure 12. When considering category A and all sub-groups in categories B and C, there 
were 13 separate analysis groups (full data set, breast, cytology, dermatology, ENT, GI, 
GU, GYN, lung, lymphoma, sarcoma, NMSC, and non-NMSC malignancies); therefore, 
percentages were calculated based on a total of thirteen groups.   
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Figure 12: Kappa categories for analyses 2.1, 2.2, 3.1, 3.2.8 
                                                        
8 Analysis 2.1: benign vs malignant (all cases), Analysis 2.2: benign vs malignant (non-neoplasms 
removed), Analysis 3.1: discrepancies in morphology (all cases), Analysis 3.2: discrepancies in 
morphology(non-neoplasms removed) 
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Analysis 2.1 had a similar kappa category distribution as analysis 1 (92% at either 
near perfect or substantial agreement and 8% at moderate agreement (lymphoma). In 
analysis 2.1 however there were more cases that showed near perfect agreement versus 
substantial agreement when in analysis 1 there were equal numbers of cases in each 
category. When non-neoplasms were removed (2.2), 85% of cases (all except NMSC and 
dermatology) had near perfect agreement and the remaining 15% had substantial 
agreement.  
 Analyses 3.1 and 3.2 had lower levels agreement overall. When including all 
cases, 8% had near perfect agreement, 23% had substantial agreement, 61% had 
moderate agreement, and 8% had fair agreement. When non-neoplasms were removed, 
15% had substantial agreement, 31% had moderate agreement, 46% had fair agreement, 
and 8% (lymphoma) did not have a kappa score calculated and therefore could not be 
categorized.   
 Kappa scores and percent agreement quantify how concordant two raters are, but 
cannot assess whether there is a treatment difference between different diagnoses. The 
discrepancies in diagnoses when including all cases are in Figure 13. This includes cases 
that did not have a comparison between the local and central diagnosis performed 
because they were an exact match in round 1 of reviews; these cases were considered 
similar for this analysis.  
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Figure 13: Analysis 4.1 - Discrepancies in diagnoses for all groups. 
On average, 32% of local diagnoses did not match the final central diagnosis; 11% of 
cases had a central and a local diagnosis that could lead to treatment differences (not 
similar). Only lymphoma (20% discrepant) and sarcoma (25% discrepant) did not meet 
the minimally acceptable threshold in healthcare of 80% agreement.  The median percent 
disagreement was 11%.  
Figure 14 includes only cases that did not have matching diagnoses in round 1 of 
reviews and therefore had an assessment of similarity between diagnoses performed by 
the authoritative reviewer during either Round 2 or 3 of the read process. 
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Figure 14: Analysis 4.2 - Discrepancies in diagnoses for all groups. 
Almost all sub-groups had near 100% mismatch between local and central diagnoses. 
Due to an application error, ten cases had a similarity assessment incorrectly triggered 
after the authoritative read even though the local and final central diagnosis were the 
same. Sixty six percent of cases on average had similar assessments, which does not meet 
the minimally acceptable threshold of agreement in healthcare. The maximum percent 
disagreement was 67% (GU and lymphoma) and the minimum percent disagreement was 
0% (ENT). The median percent disagreement was 34%.  
DISCUSSION 
Analysis 1 included all cases in the dataset. Analyses 2 and 3 were conducted 
under two sets of circumstances: including (analyses 2.1 and 3.1) and excluding (analyses 
2.2. and 3.2) non-neoplasms. ICD-O 3 coding only categorizes neoplasms; depending on 
the behavior code the specimen is either benign or malignant. This is only a general rule 
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however, as some cases are borderline between benign and malignant. These cases may 
require additional workup to better assess their behavior. Tissue growths categorized as 
in situ are examples of borderline cases; they are along the continuum of morphological 
change between dysplasia and invasive cancers.62 This level of detail was not taken into 
account for this study. Performing analyses with and without non-neoplasms permits 
insight into how the neoplasm versus non-neoplasm agreement rate affects other 
agreements at more detailed levels of categorization. For this reason, analyses 2.2 and 3.2 
should be more representative of the agreement rate for differentiating between benign 
and malignant samples and matching morphology codes, respectively.  
Analyses 1, 2.1, and 2.2 Discussion9 
Based on kappa scores, there is near perfect agreement between the central and 
local lab diagnoses in analyses 1 (neoplasm versus non-neoplasm), 2.1 (benign versus 
malignant including non-neoplasms), and 2.2 (benign vs malignant excluding non-
neoplasms) in group A (all cases in the dataset). The percent agreement for these analyses 
is above 90% as well. The high level of interrater agreement for this analysis is expected 
as it is the most general categorization of specimens. The results instill confidence that 
there are few misdiagnoses at this level.  
 Differences in levels of agreement appear when the data set is separated into sub-
groups (NMSC vs all other malignancies (group C) and by sub-specialty pathology 
reading group (group B).  In group C, NMSC had substantial kappa agreement in 
                                                        
9 Analysis 1: all cases, Analysis 2.1: benign vs malignant (all cases), Analysis 2.2: benign vs malignant 
(non-neoplasms removed) 
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analyses 1, 2.1, and 2.2, whereas all other malignancies had near perfect kappa 
agreement. All percent agreements were above 88% and surpassed the minimally 
acceptable threshold for interrater percent agreement in healthcare (80%).  
Group B divided the data set into 10 sub-specialty reading groups. Kappa scores 
ranged from 0.55 (lymphoma) to 1.00 (lung) in analysis 1. In analysis 2.1, lung and 
sarcoma had the highest kappa scores (1.00) and dermatology and GYN had the lowest 
(0.71). The kappa score for lymphoma was 0.55 but was not statistically significant. 
When non-neoplasms were removed in analysis 2.2, 6 of the 10 sub-groups had kappa 
scores of 1.00, but all 6 had sample sizes less than 10. Percent agreement ranged from 80 
to 100 percent across analyses 1, 2.1, and 2.2.   
The sample sizes for most sub-groups in group B were significantly smaller when 
non-neoplasms were removed, therefore estimated kappa scores for analysis 2.2 were less 
certain than those for analyses 1 or 2.1. Averaging many kappa scores generated from 
smaller samples may not be as accurate a representation of the true population value as a 
kappa score obtained from one large sample. This may be one reason why the average 
sub-category kappa score for analysis 2.2 and the corresponding group A kappa score 
differ (0.85 and 0.89, respectively).   
In analysis 2.1 and 2.2, most kappa scores for all sub-groups in groups B and C 
remained stable or increased when non-neoplasms were removed. This implies that the 
distinction between neoplasm and non-neoplasm is equally or more variable than the 
benign versus malignant categorization. The kappa scores for NMSC, non-NMSC 
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malignancies, and GI cases remained stable or decreased when non-neoplasms were 
removed, indicating that the distinction between neoplasm and non-neoplasm is equally 
or less variable than distinguishing benign versus malignant. The kappa score for breast 
should not be considered because the value was estimated based on percent agreement. 
The NMSC, dermatology, and non-NMSC sub-groups had the largest sample sizes in all 
analyses. Assuming that the larger sample size the more accurately the estimate reflects 
the true population value, the behavior of the kappa scores for the NMSC, dermatology, 
and non-NMSC sub-groups may be most representative of the relationship between 
including and excluding non-neoplasms and sub-group kappa scores. Had the sample 
sizes for the other sub-groups been larger, their kappa scores might have behaved 
similarly.  
When dividing the dataset into sub-groups, based on kappa scores it is unclear 
whether raters are more or less concordant in categorizing specimens as benign or 
malignant when non-neoplasms are removed from the analysis. Evaluating only sub-
groups with sample sizes over 100 in analyses 2.1 and 2.2, raters were less concordant 
when non-neoplasms were removed; otherwise, reviewers were more concordant.    
Except for breast and GI, percent agreement in groups B and C was higher when 
non-neoplasms were removed from the analysis. This is the same result in the overall 
dataset calculation. The percent agreement suggests that the distinction between 
neoplasm and non-neoplasm is more variable among raters than whether a sample is 
benign or malignant.  
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Analyses 3.1 and 3.2 Discussion10 
The group A (full dataset) kappa score and percent agreement for discrepancies in 
morphology were 0.59 and 68.3%, respectively. When non-neoplasms were removed 
(analysis 3.2), the kappa score and percent agreement were 0.52 and 57.0%, respectively. 
The average kappa score for all sub-groups (groups B and C) when non-neoplasms were 
included was 0.56; when they were not included it was 0.44. The average percent 
agreement among sub-groups when including and not including non-neoplasms was 
67.7% and 56.0%, respectively. As with earlier analyses, the difference between the 
group A and sub-group averages for kappa scores and percent agreement may be due to 
the averaging of kappa scores from smaller samples versus obtaining one kappa score 
from a larger data set. Lower agreement rates in analyses 3.1 and 3.2 are expected: 
instead of categorizing specimens into one or two categories (neoplasm versus non-
neoplasms and/or benign versus malignant), raters had thousands of ICD-O code 
combinations to choose from. Overall, kappa scores and percent agreements were higher 
when non-neoplasms were included, which implies that differentiating neoplasms from 
non-neoplasm is more consistent among raters than assigning specific diagnoses to 
samples. 
                                                        
10 Analysis 3.1: discrepancies in morphology (all cases), Analysis 3.2: discrepancies in morphology 
(non-neoplasms removed) 
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Analyses 4.1 and 4.2 Discussion11 
Diagnoses may be discrepant based on general categorization and more specific 
ICD-O codes, but the course of treatment to the subject could be the same regardless. In 
Speight’s case study, reviewer pairs agreed on a diagnosis in 69.9% of cases in the first 
round of reviews.48(p479) Comparably, in this study, two-thirds of all cases had matching 
local and central diagnoses in the first round of reviews. The remaining 33% of cases had 
diagnosis discrepancies during round 1 or rounds 1 and 2. Like analyses 2.1, 2.2, 3.1, and 
3.2, analysis 4 (discrepancies leading to differences in treatment) was conducted under 
two scenarios. The first (4.1) included all cases regardless of whether a similarity 
assessment needed to be performed. The second excluded cases where a similarity 
assessment did not occur because there was an exact ICD-O code match in the first round 
of reviews (4.2). The separate analyses tier cases into less challenging and more 
challenging and assumes that cases requiring additional review after round 1 are more 
challenging than those that do not. Differences in agreement between the two levels can 
elucidate where discrepancies exist and their implications.   
When all cases were considered regardless of number of rounds of review 
(analysis 4.1), about 90% of diagnoses would have similar courses of treatment. All sub-
groups except sarcoma reached the minimally acceptable agreement rate in healthcare 
(80%). Likewise, in Speight’s case study, 92.7% of cases reached a final diagnosis after a 
                                                        
11 Analysis 4.1: All discrepancies leading to differences treatment (cases NOT similar), including 
those identified in categories 1, 2, and 3, Analysis 4.2: All discrepancies leading to differences 
treatment (cases NOT similar), including those identified in categories 1, 2, and 3 (cases where LPR 
and central diagnosis matched in the first round of reviews removed) 
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third adjudicator looked at cases with discrepant assessments in the first round of 
reviews.48(p479) In the remaining 33% of cases that did not have matching diagnoses in 
round 1 (analysis 4.2), 34% may have different courses of treatment depending on 
whether the local or central diagnoses was used. Details regarding percentage of cases 
without matching diagnoses in round 1 per sub-group are in Table 17. 
Table 17: Cases with round 2 and/or round 2 and 3 reviews per sub-group. 
Group Percent of Cases with Round 2 and/or 3 Reviews 
All cases 33.39 
NMSC 47.08 
Non-NMSC 24.17 
Breast 24.14 
Cytology 33.33 
Dermatology 48.22 
ENT 41.18 
GI 27.27 
GU 7.14 
GYN 38.89 
Lung 18.18 
Lymphoma 30.00 
Sarcoma 62.50 
 
No sub-groups except GI, lung, and ENT met the minimally acceptable threshold of 
agreement (80%) in analysis 4.2.  The local and central diagnoses for all ENT and lung 
cases that went past round 1 of reviews were considered similar (100% agreement); 81% 
of GI cases were considered similar. GU and lymphoma had the highest levels of 
disagreement at 67%. 
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 Although non-melanoma skin cancers and all other malignant processes both 
represent malignant processes, the significant differences between them are important 
from a safety perspective. Cancers that are not non-melanoma skins cancers tend to be 
harder to treat, have higher mortality rates, and are more serious safety concerns that non-
melanoma skin cancers. The risk of dissimilar diagnoses that could potentially lead to 
different treatments was comparable for both NMSC and non-NMSC malignancies, 
despite kappa scores and percent agreements for non-NMSC malignancies being higher 
in all analyses except analysis 2.2 (difference of less than 2%). NMSC had a slightly 
higher risk of dissimilar diagnoses in analysis 4.1, but when looking at challenging cases 
only, NMSC had a 33% risk and other malignancies had a 36% risk of dissimilar 
diagnoses. Equal attention needs to be paid to both sub-groups, as neither category seems 
to significantly increase risk of incorrect treatment.   
The adjudication model used in Speight’s study and in this study differ slightly. In 
Speight’s study, in the case of discrepancy between reviewers A and B, the case went to 
an adjudicator. If a final diagnosis could not be decided, the case went to a consensus 
review. In this study, in the case of discrepancy between reviewers A (site pathologist) 
and B (central pathologist 1 or PR1), the case went an additional central pathologist 
(PR2). If PR2 and PR1 do not agree on a diagnosis, then the case went to a final central 
pathologist (adjudicator or PR3). PR3 in this study replaced the consensus review in 
Speight’s study. This study also had a similarity assessment component. The results in 
both studies however were comparable: the percent of cases with similar (as defined in 
this study’s charter) diagnoses increased with additional rounds of reviews.     
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Special Considerations 
Charter and CPC/Reviewer Manual Updates 
 
Although the charter, CPC manual, and reviewer manual were updated at various 
points throughout the study, these changes should have had minimal to no impact on the 
diagnosing of specimens. Tables 6 (charter) and 7 (reviewer/CPC manuals) indicate the 
document updates that may affect assessments in bold. These updates were further 
assessed to determine whether they may have had an impact on the analyses performed in 
this study. The only charter update that may have changed how cases were being assessed 
mid-study was the addition of clear definitions of slide quality. This change was made in 
revision 4.0. Seventy-seven percent of cases were read before revision 4.0 of the charter 
was made effective. Reviewers may have categorized slides differently before and after 
the update. Slides with poor quality were excluded from the analysis, so 
miscategorization of slide quality could have led to improper inclusion or exclusion of 
samples. Based on the conservative approach taken by this adjudication committee, it is 
likely that a reviewer would downgrade slide quality versus upgrade; the risk is low that 
slides with poor quality were categorized as having fair or good quality. Therefore, it is 
more likely that cases with acceptable quality were excluded than that cases with poor 
quality were included. Under this assumption, little to no data included in this analysis 
could have been generated from slides of low quality.  
Two updates made in revision 2.0 to the reviewer and coding manuals may have 
affected how specimens were read. Eighty-two percent of cases were read before revision 
2.0 of the reviewer and CPC manuals was effective. The first update referenced newly 
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added info buttons regarding the definitions of neoplasm and non-neoplasm; the second 
update was the addition of clarifying instructions regarding histology and behavior code 
selection. Prior to the introduction of the info buttons, reviewers/CPCs defined specimens 
as neoplasms or non-neoplasms based on their own interpretation of the terms. After the 
introduction of the info buttons, reviewers/CPCs could view the standardized definitions 
being used across the program before making an assessment. The risk of incorrect 
identification of a specimen as a neoplasm or non-neoplasm previous to the inclusion of 
the info buttons is low; understanding the difference between the two terms is part of 
normal coding and pathology education and practice.  
Additional instructions that may have impacted assessments were added to the 
CPC and reviewer manuals in revision 2.0. The instructions did not change the review 
process but instead captured information which had already been imparted to the CPC 
and review teams over email and verbal communications. The instructions were to 1) 
select the most specific histology and behavior code and avoid general/non-specific codes 
unless no other code corresponded to the assessment and 2) if no code adequately 
described the diagnosis, the most appropriate code should be chosen and comments 
should be provided. These updates should not have had a significant impact on 
assessments even though they are directly pertinent. The introduction of instruction 2 
most likely did not affect the actual selection of a code because reviewers were always 
required to choose a morphology code if they categorized the specimen as a neoplasm. 
The only difference in cases assessed before and after the reviewer/CPC manual update 
would have been the requirement of adding a comment. Implementation of instruction 1 
  72 
could have increased or decreased discrepancies. Discrepancies between general and 
specific codes may have decreased after the change, but this did not ensure that the more 
specific codes that were chosen were not also discrepant.  
Processing specimens 
 
In Speight’s study, reviewers A and B reviewed different sets of slides during the 
first round of review. Understanding how assessing different sets of slides for the same 
sample affects interrater variability is important, because assessments made on different 
sets of slides could increase the likelihood of discrepancy. Although it is possible that in 
any case the slides assessed by the site and central lab were not the same, in processed 
cases, the slides used to make the diagnosis by the site and the central lab were 
guaranteed to be different. Table 18 shows the number of specimens processed (either 
slides were cut and stained from blocks provided by the site or unstained slides provided 
by the site were stained) at the CRO-contracted (central) lab in each reading sub-group. 
Overall, 10.13% of cases in the dataset required processing. The dermatology and GI sub-
specialties were taken as examples for this analysis because they had the most processed 
cases. 
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Table 18: Number of cases processed at central lab per sub-group. 
Sub-Specialty Number of Cases Processed 
Breast 6 
Dermatology 24 
GI 12 
GU 8 
GYN 6 
Lung 1 
Lymphoma 2 
OTHER 1 
Sarcoma 1 
Grand Total 61 
  
For analyses 2.1 and 3.1, processed cases constituted 9.5% of the dermatology sub-group 
and 12.1% of the GI sub-group. When non-neoplasms were excluded (analyses 2.2 and 
3.2), processed cases made up 9.0% of dermatology sub-group and 16.7% of the GI sub-
group.  
The kappa scores and percent agreements for analyses 2.1 and 2.2 separated by 
sub-group (dermatology or GI) and processing status (processed or not processed) are in 
Table 19. For sub-groups in bold, the upper boundary of the confidence interval 
exceeded 1.00. 
 
 
  74 
Table 19: Interrater Variability Results Based on Processing (GI and Dermatology) 
– Analyses 2.1 and 2.2.12 
GI case outcomes were less variable than those for dermatology regardless of processing 
status and analysis. Processed dermatology cases had less variable outcomes than the 
non-processed dermatology cases in both analyses. Based on these results, processing 
does not seem to have a significant impact on kappa scores when distinguishing between 
benign and malignant samples (analyses 2.1 and 2.2).  
The relationship between processing and assigning specific morphologies is less 
clear. The kappa scores and percent agreements for analyses 3.1 and 3.2 separated by 
sub-group (dermatology or GI) and processing status (processed or not processed) are in 
Table 20. For sub-groups in bold, the upper boundary of the confidence interval 
exceeded 1.00. Sub-groups in italics were not statistically significant based on the 
confidence interval and p-value. 
 
                                                        
12 Individual Pathology Sub-Specialty Reading Groups: Analysis 2.1: benign vs malignant (all cases), 
Analysis 2.2: benign vs malignant (non-neoplasms removed) 
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Table 20: Interrater Variability Results Based on Processing (GI and Dermatology) 
– Analyses 3.1 and 3.2.13 
 
All kappa scores decreased from analyses 2.1 and 2.2 to analyses 3.1 and 3.2. The 
kappa scores for both GI and dermatology processed cases in analysis 3.2 were not 
statistically significant. Similarly to categorizing specimens between benign and 
malignant, when non-neoplasms were included (analysis 3.1), all GI cases regardless of 
processing status had higher kappa scores (0.62 processed and 0.53 not processed) than 
those for dermatology (0.32 processed and 0.46 not processed). Even though the GI sub-
group had a higher percentage of processed cases, again the outcomes between the central 
and local labs were less variable than outcomes in the dermatology sub-group. 
When non-neoplasms were removed however (analysis 3.2), all kappa scores 
decreased. The pattern in analyses 2.1, 2.2 and 3.1 was not present here. In analysis 3.2, 
the highest kappa score was for GI processed cases, followed by dermatology cases that 
were not processed, then GI cases that were not processed, and finally processed 
dermatology cases. The kappa scores for both processed groups were not statistically 
                                                        
13 Individual Pathology Sub-Specialty Reading Groups: Analysis 3.1: discrepancies in morphology (all 
cases), Analysis 3.2: discrepancies in morphology (non-neoplasms removed) 
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significant, so the ordering above might not be representative of the true order of the 
population.  
Dermatology morphology has far more minutiae and therefore potential for 
variability than that for GI, which may explain why GI kappa scores were greater than 
those for dermatology in almost all analyses and categories (conversation with Dr. Glenn 
Bubley, July 5, 2017). The complexity of dermatology cases is so great, that even when 
GI slides reviewed at the site and at the central lab were guaranteed to be different, the 
kappa scores for all GI cases were still higher than those for any dermatology cases.  Due 
to the small sample sizes and uncertainty in the results for processed cases in analysis 3.2, 
it is difficult to make a conclusion on the effects of processing on assigning specific 
morphology of neoplasms.  
The results for discrepancies in diagnoses and potential treatment differences 
(analysis 4.1 and 4.2) are in Table 21. 
 
 
 
 
  77 
Table 21: Discrepancies in diagnosis and treatment results based on processing (GI 
and Dermatology) – Analyses 4.1 and 4.2.14 
  
Percent Mismatch 
between Local and 
Central Diagnosis 
Percent Dissimilar 
leading to different 
treatments N 
Analysis 
4.1 
Dermatology 
Processed 58 29 24 
 
Dermatology Not 
Processed 45 16 229 
 GI Processed 25 0 12 
 GI Not Processed 25 6 87 
Analysis 
4.2 
Dermatology 
Processed 82 41 17 
 
Dermatology Not 
Processed 99 34 105 
 GI Processed 74 0 4 
 GI Not Processed 96 22 23 
 
In analysis 4.1, GI processed and not processed cases had the same percentage of 
mismatched diagnoses between the local and central labs, but non-processed cases had 
more discrepancies leading to treatment differences. Processed dermatology cases had a 
higher rate of mismatched diagnoses and discrepancies leading to treatment differences. 
In analysis 4.2, dermatology and GI cases that were not processed had more discrepant 
diagnoses than processed cases. Processing led to a larger percentage of treatment 
differences in the dermatology sub-group, but a smaller percentage of treatment 
differences in the GI sub-group. This may be due to the lower number of morphology 
                                                        
14 Individual Pathology Sub-Specialty Reading Groups: Analysis 4.1: All discrepancies leading to 
differences treatment (cases NOT similar), including those identified in categories 1, 2, and 3, 
Analysis 4.2: All discrepancies leading to differences treatment (cases NOT similar), including those 
identified in categories 1, 2, and 3 (cases where LPR and central diagnosis matched in the first round 
of reviews removed) 
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code combinations in this data set for GI (28) versus dermatology (71), however this 
difference may just be due to the higher number of dermatology cases overall.                      
Kappa score vs Percent Agreement 
 
Kappa scores and percent agreement only provide estimates of concordance 
between raters. The true rate of discordance is nearly impossible to quantify with the 
statistical tools currently available. The kappa and percent agreement statistics are not 
directly comparable. For example, in analysis 2.2, the kappa score for dermatology was 
0.61, yet the percent agreement was 96.4%. In a study comparing automated versus 
human visual detection of abnormalities in biological samples, similar findings were 
noted. Results showed only moderate agreement between the human and the automated 
detection, but the percent agreement generated from the same data showed 94.2% 
agreement.63 According to the kappa score, there was (barely) substantial agreement, but 
based on percent agreement there was nearly perfect agreement. 
Mary McHugh tries to address the gap between kappa scores and percent 
agreement by interpreting Cohen’s kappa as not only a measure of agreement, but 
disagreement as well. She extrapolates estimates of reliability of data from the kappa 
score as an approximate comparator for percent disagreement. Stricter categorization of 
levels of agreement also better reflect the implications of different levels of disagreement. 
This interpretation is in Table 22.49(p4)  
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Table 22: McHugh kappa interpretation.49(p4) 
Value of 
Kappa (Cohen) 
Value of Kappa 
(McHugh) 
Level of 
Agreement (Cohen) 
Level of 
Agreement 
(McHugh) 
% of Data that are 
Reliable (McHugh) 
0.01-0.20 0.00-0.20 None to Slight None 0-4% 
0.21-0.40 0.21-0.39 Fair Minimal 4-15% 
0.41-0.60 0.40-0.59 Moderate Weak 15-35% 
0.61-0.80 0.60-0.79 Substantial Moderate 35-63% 
0.81-1.00 
0.80-0.90 Almost Perfect Strong 64-81% 
Above 0.90 Almost Perfect 82-100% 
 
In this study, the average kappa score for neoplasm versus non-neoplasm and benign 
versus malignant categorization could be considered almost perfect based on Cohen’s 
stratification, but only strong based on McHugh’s. The average kappa score for 
discrepancies in morphology codes change from moderate to weak agreement when using 
McHugh’s stratification. The most significant difference between McMugh and Cohen’s 
kappa categorizations is the interpretation of kappa scores above 0.80. Cohen prescribes 
one level of agreement to scores between 0.81 and 1.00 (almost perfect) where McHugh 
has two (strong versus almost perfect). Although the difference may seem negligible 
qualitatively, from a data reliability standpoint the difference may be significant. Strong 
agreement implies 64-81% data reliability whereas almost perfect agreement implies 82-
100% data reliability.    
The kappa score and percent agreement both have limitations. The kappa score 
considers chance agreement: the greater the expected chance agreement, the lower the 
kappa score. The chance agreement depends on the marginal sums of the chi-square table 
on which the statistic is based. The expected chance agreement depends on the following 
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assumptions: raters guess on every item, raters guess at rates similar to the marginal 
proportions, and raters are entirely independent. These assumptions cannot be confidently 
verified. Statistical significance of kappa scores is also difficult to ascertain when there is 
inconsistency with scoring; variability in assessments is exactly what the kappa score 
measures. Large confidence intervals may also span many levels of agreement which 
makes it difficult to obtain true meaning from the kappa score itself. Percent agreement 
assumes that the majority result is correct and the minority result is incorrect; for 
example, if there is 90% agreement, the values in the 90% are correct and the values in 
the remaining 10% are not. Percent agreement also assumes that raters make informed 
and deliberate choices in all assessments. Like kappa score conditions, these premises can 
also not be verified with confidence.49(p2-8)  
Neither kappa scores nor percent agreement can completely quantify or explain 
interrater variability. Understanding the strengths and weaknesses of each can help 
identify when one might be more applicable than the other. If subjective assessments (i.e. 
presence/absence of abnormal morphology in a biological specimen) inherently have 
more guesswork than objective assessments (i.e. lab values), then kappa scores might be 
more useful in assessing interrater variability for subjective assessments. Percent 
agreement might be more suitable for objective assessments. In a healthcare setting, it is 
best practice to consider both statistics.  
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Limitations and Future Studies 
There are two major limitations for this study. The first is small sample sizes. 
Although the overall sample was substantial (N=602), when the dataset was divided into 
sub-groups the sample sizes were not large enough to generate results with confidence. 
As a result, the confidence intervals for many of the kappa scores were very wide, 
spanning multiple levels of agreement. Per McHugh, sample sizes should never be less 
than 30 and ideally should exceed 1,000 in order to get the most accurate and dependable 
statistics.49(p8) It is possible that due to small sample sizes the kappa scores and percent 
agreements generated as part of this study are misrepresentations of the true population 
averages.  
The second limitation is that the information used to make an assessment at the 
site was most likely not the same as that used by the central pathologists. Except in cases 
where processing was performed at the central lab, there is no way to confirm that the 
slides sent to the central lab are the same slides and/or cut from the same tissue block that 
were used to make the diagnosis at the local lab. Tissue samples on most slides are very 
small and could easily represent different parts of a lesion/tumor even if they are cut from 
the same tissue block. For example, one slide could have tissue taken from a tumor 
margin and show no malignancy; another sample could be taken from the center of the 
same tumor and show evidence of malignancy. Although processing of blocks at the 
central lab didn’t seem to have a significant effect on kappa scores or percent agreement, 
this does not imply that if a larger number of specimens were known to be discrepant 
there wouldn’t be an effect on either statistic. 
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In addition to slides, there is almost certainly a discrepancy in supporting clinical 
information provided to the local and central labs. In most clinical practices, the 
pathologists receive clinical histories, impressions, and additional supporting documents 
from surgeons and other specialists who have also examined the subject. In this study, the 
central pathologists made assessments in isolation; they only received (if available): 
biopsy date, biopsy type and details if “other” was selected, anatomic location and details 
if “other” was selected, number of blocks provided, number of slides provided, and stain 
types. Without supporting information, the central pathologists may inadvertently create a 
discrepancy between central and local diagnoses due to lack of context. For example, 
certain skin lesions can present as multiple disease processes; a lesion can have features 
of both basal cell and squamous cell carcinoma. It is up to the pathologists’ discretion to 
choose the most appropriate assessment with the information available. With additional 
clinical history and other information, the central pathologist could make a more 
confident assessment with less guesswork. Due to this limitation, the current read model 
does not allow for a “true” comparison between local and central diagnoses. It can be 
argued, however, that local pathologists have access to too much clinical information, 
which can skew their assessments. Instead of looking at the sample independently, the 
local pathologists are primed to look for clinically suspected or suggested pathology 
indicated on supporting documentation.  
It also cannot be assumed that local diagnosis was the result of a single 
pathologist; it is possible that multiple pathologists collaborated to reach an assessment. 
If the local diagnosis was agreed upon by more than one pathologist, then, based on the 
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social and probability theories through which Speight supports adjudication, the site 
diagnosis may also have a higher probability of being correct than if the diagnosis was 
made by a single pathologist. If this were the case then it would be hard to determine 
whether the site or central assessment was more likely to be correct.   
Future studies should ensure that each sub-group has sufficient samples to yield 
more exact results with smaller confidence intervals. All efforts should be made to obtain 
the same slides that were made to make the local diagnosis for central review. This will 
require adequate training, close monitoring, and cooperation by sites and the sponsor and 
may not be truly feasible. The workflow and read paradigm should be updated to permit 
presentation of select clinical information to the central pathologists. Although local 
pathologists may have too much supporting documentation, controlling what is available 
to local pathologists is not feasible. To maintain independence, the final diagnosis and 
clinical impressions should not be provided to the central pathologist, but medical history 
and macroscopic descriptions would be sufficient. The medical history provides 
background information on why the biopsy may have been obtained as well as any pre-
existing conditions that may impact the current diagnosis. The macroscopic description 
details the shape, size, color, texture, and other defining characteristics of the specimen, 
which can be helpful in determining underlying pathology.  
The current analyses could be performed excluding all cases with a behavior code 
of 1 (uncertain whether benign or malignant - borderline malignancy, low malignant 
potential, or uncertain malignant potential) in order to more clearly categorize all 
samples. Additional analyses should be performed, including comparing all independent 
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reads for each case, not just the authoritative read, to the local lab result and to each 
other. These analyses would provide more insight into whether there is consistency 
among reviewers in how they assess cases/agreement of their assessments and the local 
results.   
CONCLUSION     
If it is the case that there are clinically significant discrepancies between local and 
central diagnoses and that, based on Speight and Surowiecki’s theories, central 
adjudication yields more accurate diagnoses than a local pathologist, then it should be 
accepted that adjudication ought to be more widely used in clinical trials to assess 
histopathology-related safety outcomes and endpoints. Based on this study’s results, risk 
of inaccurate representation of high level (neoplasm versus non-neoplasm and benign 
versus malignant) safety and risk for a compound under investigation is low regardless of 
whether local or central diagnoses are considered. Safety and risk profiles including 
information about unique pathologies were more variable, and using adjudicated data 
should be considered. Despite inexact matches, many ICD-O codes can represent similar 
diseases processes with similar treatments. Understanding whether the lack of agreement 
stems from small inconsequential coding differences or misdiagnosis is important and 
can only be determined with confidence by a pathologist, not statistics. Due to small 
sample sizes, it cannot be confidently stated whether adjudication would have equal 
benefit among all pathology sub-specialty groups. There is little discord between the 
local and central pathologists regarding whether malignancies exist among samples. 
There are, however, significant discrepancies regarding specific morphology ICDO- 3 
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codes and their associated treatments. Because there is a significant difference between 
local and central pathologists in assigning diagnoses, adjudication should be used when 
providing a safety profile for a compound because it is more specific and more accurate. 
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APPENDIX 
Mathematical model for 3 step adjudication process as determined by Speight, et al. 
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THERAPEUTIC AREA EXPERTISE:   
Indication Phase # Patients # Sites Countries 
Various 
Autoimmune 
Indications 
I-IV 
100-
>5000 
(variable 
per 
protocol) 
10->200 
(variable 
per 
protocol
) 
Global 
Breast 
Cancer 
I 117 5 United States, United Kingdom 
Metastatic 
Carcinoma/
Melanoma/N
on-Small 
Cell Lung 
Carcinoma 
I 700+ 37 
United States, Canada, France, 
Australia, United Kingdom, 
Germany 
Myelofibrosi
s/Post 
essential 
thrombocyth
emia 
mylofibrosis/
Post 
polycythemia
II 150 60 United States 
  100 
vera 
myelofibrosi
s 
Metastatic 
Pancreatic 
Adenocarcin
oma 
II 244 112 
United States, Russia, Germany, 
Poland 
Colorectal 
Adenocarcin
oma 
II 265 154 
United States, France, Italy, 
Spain, Germany, Poland 
Breast 
Cancer 
II 255 120 
United States, Poland, Russia, 
Australia, France, Brazil 
Argentina, Czech Republic, 
Denmark, Israel, Norway, 
Slovakia, Hungary, Canada, 
Ukraine, Belgium, Sweden, 
Spain, Netherlands, Finland 
Pancreatic 
Cancer 
II 82 22 China 
Hand 
Osteoarthritis 
IIa 120 50 
United States, Belgium, France, 
Netherlands, 
Prostate 
Cancer 
III 1800 207 
Austria, Belgium, Denmark, 
Finland, France, Germany, Israel, 
Lithuania, Netherlands, Poland, 
Slovakia, Spain, Sweden, United 
Kingdom 
Breast 
Cancer 
III 712 140 
United States, Spain, Belgium, 
Poland, Germany, Russia, 
France, Italy, United Kingdom, 
Sweden, Denmark, Thailand, 
Hungary, Greece 
Non-Small 
Cell Lung 
Cancer 
III 850 225 
United States, Austria, 
Netherlands, Slovenia, Spain, 
France, Poland, Canada, Russia, 
Belgium, Germany, United 
Kingdom, Czech Republic, 
Romania, Bosnia, Serbia and 
Montenegro, Croatia, Hungary, 
Ukraine, Italy 
  101 
Breast 
Cancer 
III 238 422 
United States, Canada, Australia, 
Belgium, France, Germany, Italy, 
Netherlands, Portugal, Romania, 
Russia, Taiwan, Ukraine, South 
Korea, Mexico, Switzerland, 
Ireland, Japan, United Kingdom, 
Turkey 
Metastatic 
Soft Tissue 
Sarcoma 
III 65 500 
United States, Spain, Hungary, 
Belgium, France, Russia, Italy, 
Germany, Poland, Denmark, 
Austria, Israel, Australia, Canada 
Venous 
Thromboemb
olism 
III 6000 518 
United States, Spain, Croatia, 
Czech Republic, Finland, 
Canada, Austria, Belgium, 
Bulgaria, France, Serbia and 
Montenegro, Slovakia, Germany, 
Denmark, Singapore, Hungary, 
Israel, Italy, Lithuania, Poland, 
Russia, South Africa, United 
Kingdom, Australia, India, 
Estonia, Latvia, Argentina, 
Brazil, Chile, Peru, Romania, 
Ukraine 
Pediatric 
Type 2 
Diabetes 
Mellitus l 
III 107 172 
United States, Belgium, Croatia, 
Denmark, Germany, Greece, 
Hungary, Macedonia, Serbia and 
Montenegro, Spain, Sweden, 
United Kingdom, India, Israel, 
Mexico, Russia, Turkey, Canada, 
Norway, Romania, 
  102 
Pediatric 
Type 2 
Diabetes 
Mellitus 
III 165 360 
United States, Russia, Italy, 
Thailand, Chile, Israel, 
Dominican Republic, Costa Rica, 
Guatemala, Colombia, Mexico, 
Romania, Lithuania, New 
Zealand, Latvia, Bulgaria, 
Malaysia, Spain, Argentina, 
Hungary, Serbia and 
Montenegro, Austria, Portugal, 
Slovakia, Poland, Denmark, 
Philippines, Australia, Brazil, 
Germany, South Africa, Sweden, 
Canada, France 
Hip and 
Knee 
Osteoarthritis 
III 375 80 United States 
Nail 
Psoriasis 
III 6 5 United States, Belgium, Germany 
 
 
